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Numerous studies have suggested the correlation between the stability of protein com-
plexes, the importance of Protein Protein Interactions (PPIs) and the resulting molecular
mechanisms for the underlying protein functions. In particular, the three-dimensional (3D)
properties of protein binding interfaces are thought to embed key roles in mediating bio-
logical activities and in regulating cellular functions. The alteration of binding interfaces
can disrupt the biological system in cell and consequently result in different phenotypic
traits or diseases. In a scenario in which the rapid growth of biologically relevant informa-
tion contributed by large-scale sequencing projects has paved the way to insights into the
relationship between genotype and phenotype, it is really important to effectively combine
all available information playing a role in this, to extract some principle rules guiding our
understanding on the occurring molecular and atomistic mechanisms.
It is therefore timely to implement large-scale studies on the role of gene variants on
Protein-Protein Interaction Networks (PPINs) and more specifically protein complexes.
The objective of this project is a proteome-wide scale analysis of Protein Interaction data
by mapping human genetic variation data onto structurally determined binary protein
complexes. 3D PPINs were used as a tool to extract the association between human
proteins and to enable an insight into molecular features of human genetic variation. A
iii
comprehensive literature review on the topic of PPINs is given in Chapter 1 (”Introduc-
tion to Protein-Protein Interactions and Networks”). Non-synonymous Single Nucleotide
Polymorphisms (nsSNPs) were the main focus in this study since they can directly cause
conformational changes of proteins or failures in forming protein complexes. Two disease-
related nsSNP datasets were investigated including: a) germ-line disease nsSNPs and b)
somatic cancer nsSNPs. A set of nsSNPs which are known not to be related to diseases
was used as the background to be compared with the chosen disease nsSNPs in order to
highlight the characteristic properties identifying the features of disease nsSNPs. A sur-
vey on human genetic variation and the current state of related studies is presented in
Chapter 2 (”Human Gene Variants”). The study of inter-domain disordered regions was
also included in this project, as recent studies suggested their importance in regulating
biological functions. An introduction on protein ”Intrinsic Disorder” is also presented in
Chapter 2.
An automated system pipeline was developed in this study to generate structure-integrated
PPINs at protein domain level, map nsSNPs onto these structures, and classify nsSNPs.
The collected nsSNP datasets are classified by their occurrence in different protein regions,
including surface, interface, core and disordered. The detail of the pipeline development is
given in Chapter 4 (”Pipeline to Generate 3D Protein-Protein Interaction Networks”). The
interface regions showed a previously documented enrichment with disease-related nsSNPs.
In addition, our results showed that germ-line disease nsSNPs and somatic cancer nsSNPs
exhibit distinctive features in terms of their physical-chemical preferences and functional
specificity. This may suggest that these two types of disease-related nsSNPs affect cellular
functions through different mechanisms. Moreover, the functions of affected proteins were
found to be highly related to the types of diseases the germ-line nsSNPs lead to. These
iv
results will be presented together in Chapter 3 (”Computational Analyses of Disease-
related Variants”).
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Protein-Protein Interaction Networks (PPINs) are a powerful tool to study biological pro-
cesses in living cells. In this chapter, we present the progress of PPIN studies from abstract
to more detailed representations. We will focus on 3D interactome networks, which offer
detailed information at the atomic level. This information can be exploited in under-
standing not only the underlying cellular mechanisms, but also how human variants and
disease-causing mutations affect protein functions and complexes’ stability. Recent studies
have used structural information on PPINs to also understand the molecular mechanisms
of binding partner selection. We will address the challenges in generating 3D PPINs due
to the restricted number of solved protein structures. Finally, some of the current use
of 3D PPINs will be discussed, highlighting their contribution to the studies in geno-
type–phenotype relationships and in the optimization of targeted studies to design novel
chemical compounds for medical treatments.
1
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This chapter has been published as a review paper [1] which is attached in Appendix
B. The first draft of the review was completed by the first author under supervision of
Prof. Franca Fraternali. The content contributed by other authors to the published review
includes:
• Mapping of functional pathway for cancer studies (Page 5 paragraph 1 of this thesis).
• Protein allosteric regulation (Page 6 from line 22 to the end of the paragraph, and
Page 7 line 15 of this thesis).
1.1 Introduction
Most biological processes in a living cell, such as transcription regulation, signal trans-
duction and cell motility, are mediated by Protein–Protein Interactions (PPIs). Network
representations effectively address the complexity of PPIs in biological systems. Indeed,
networks provide a highly compact and comprehensive view of binary relationships, in
which nodes represent proteins/genes and edges indicate functional association or physical
interactions between protein/gene pairs (Figure 1a). Many studies used network analysis
to report proteins/genes involved in a particular disease or function [2, 3], and to com-
plement large–scale siRNA screenings [4, 5]. The network topological properties of genes,
including the degree of interactions, the clustering coefficient and the betweenness, which
are the measurements of connectivity, interconnectivity and centrality, respectively, are of-
ten used to characterize topological features of a network [6, 7] and provide useful insights:
for example, cancer proteins were found to have distinguishable topological features to the
other proteins. These are generally found to be hub proteins with relatively high centrality
[8, 9]. Network representations can also be used to study the associations between objects.
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In the study of Goh et al. [10], a human diseasome bipartite network was constructed to
model associations between genes and diseases. A link between a disease and a disease
gene indicates that mutations in that gene are resulting in the specific disease. Many
diseases were found to share a common genetic origin. This was an interesting finding
which suggested that diseases may not be as independent of each other as we know from
the traditional clinical assessment.
Apart from disease-related studies, PPINs are also often used in functional studies to
assign putative functions to newly discovered genes [11, 12] using algorithms based on the
Guilt-by-Association principle (Figure 1B). This has been particularly explored for plant-
specific proteins [13, 14, 15] as the majority of these protein functions remain unknown,
and yet it is critical to understand their biological relevance and the involving biological
processes, including growth control and genotype–phenotype relationships for the variety
of plants.
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Figure 1.1: The scale of the biological system versus the amount of information
a protein–protein interaction network contains.(A) The human protein–protein in-
teraction network. (B) Guilt–by–Association principle in predicting protein functions.
(C) 3D RAF1 sub–network containing information from system level to atomic level. The
nodes represent proteins, whereas the edges are annotated with protein complexes. The
structural information in a 3D PPIN can be used to study the promiscuity of interface
residues. (D) The structure of protein complex. The interface regions are shown with shape
sphere and mapped with disease-causing nsSNVs (coloured in red). (E) The atomic-level
view of interface with nsSNVs. (F) A drug inhibits the binding pocket. Figure adapted
and modified from Lu et al. [1].
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Another approach is based on integrating genomic information and PPIN with the knowl-
edge of functional pathways [16], which can be retrieved from databases, such as Kyoto
Encyclopedia of Genes and Genomes (KEGG) [17]. These mapping has been particularly
exploited for cancer studies. Genomic perturbations attributed to diseases can be mapped
on biochemical pathways so as to obtain a pathway-level understanding at distinct disease
states. It has been demonstrated that when cancer patients harbour genomic alterations
or aberrant expression of different genes, these participate in a common pathway or have
a similar effect in altering the pathway [18, 19].
These studies supported by PPINs have brought novel insight into cellular functional
modules and the association between genes and diseases. By integrating PPINs with the
atomic-level information (Figure 1c), one can understand more precise details on the mech-
anisms regulating how proteins specify their functions and how disease-causing mutations
disrupt the biologically functional systems.
Pioneering studies in structure-based PPINs were done by Aloy and Russell [20] who looked
into atomic details of protein interaction pairs and proposed that homologous protein
pairs may interact in the same way, using the same binding interfaces. In the effort
of bridging the gap between large-scale PPI determination and structural data, hybrid
approaches to structure determination of macromolecular complexes have been proposed
[21, 22, 23]. Integration of structural data at different resolution and reliability has been
successfully used to reconstruct hybrid assembly structures that can be informative for
further PPI validation studies or in designing new tailored structural investigations. These
3D network studies were initially done on the model organism yeast. Recently, in reason
of the increasing number of available structures and interaction data, 3D PPINs of other
organisms have also become available [24, 25], including human, mouse, drosophila, and
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bacteria.
Recent studies [26, 27, 28, 29, 30] integrated protein structural information with PPINs to
give the ability to implement large-scale studies on the association between cellular mech-
anism and protein complexes. One of the major interests in exploiting these studies is to
investigate how disease-related mutations may disrupt protein functions and ultimately
affect the function of biological systems. Mutations can be classified as loss of function,
gain of function or neutral according to their effect on protein function. These effects can
be mediated by alterations of the protein stability induced by the mutation [31, 32]. For
example, the B-RAF kinase is widely mutated in cancer and the V600E mutant, recently
observed also in patients with granulomatous paediatric disease [33], destabilises the inac-
tive conformation of the kinase. This gain-of-function mutant keeps B-RAF in the active
state and consequently increases the activation of another kinase ERK [33]. Mutations
can affect protein function also by modifying the affinity of the protein for its partners.
For example, mutations derived from Glioblastoma patients have been recently shown
to destabilise the complexes of the proteins involved in the disease pathogenesis, mainly
through a decrease of the electrostatic contributions to the binding energy [28]. Drastic
amino acid changes at the protein interface, where a protein is in physical contact with an-
other protein, can significantly change the binding energy of the interaction. In particular,
the occurrence of mutations at the interface hot spot residues, which contribute the most
to the binding energy [34, 35], are most likely to have impact on the interaction, so that
the proteins would either lose interactions with the partner proteins or gain interactions
with new binding proteins. Additionally, protein function can be altered by mutations oc-
curring at allosteric sites. Indeed, allosteric mutations can disrupt or promote the binding
of allosteric modulators, affect the communication pathways between the allosteric and
Chapter 1. Introduction to Protein-Protein Interactions and Networks 7
orthosteric sites and modify the relative proportion of inactive/active conformations [36,
37]. For example, different cancer-related mutations in kinases have been shown to involve
a shifting in the relative population of the inactive/active states [38, 39].
Besides providing insight into the impact on the complex functionality of disease-causing
mutations, 3D PPINs can be used for large-scale screenings of drug targets to compensate
experimental drug compound screening methods [40]. A number of approaches have been
developed in the recent years to exploit PPINs in drug discovery, as the cellular network
and the surrounding environment are essential part of the process of efficient drug targeting
and delivering. By implementing large-scale screening over protein molecular properties,
one could identify new target proteins and potential binding sites of drug compounds. In
particular, PPINs can be used to identify PPI inhibitors. Targeting PPIs is still one of
the most challenging tasks in drug design, owing to the significant differences between in-
terfaces in PPIs and small molecule binding sites. However, specific properties embedded
in PPI interfaces and needed for partners recognition can be exploited to identify drug
compound targets [41, 42, 43, 44, 45]. Indeed, there are increasing examples of targeting
PPIs (Figure 1f) with drugs that can bind to transient and dynamic pockets in orthos-
teric or allosteric sites (for a review on the subject, see Engin et al. [46] and references
therein). In targeting PPIs, people are also exploiting Protein-Interface Motifs to identify
potential off-target drugs [47]. Databases such as Interactome3D [24] and INstruct [25]
provide PPINs annotated with protein complexes and are essential to large-scale screening
approaches targeting protein interfaces in drug design [48].
Another interesting use of targeting PPIN, pathways and drug action mechanisms is the
identification of proteins that induce drug side effects [49]. Drug side effects are often
the most undesirable outcomes from medical treatment, frequently caused by the binding
Chapter 1. Introduction to Protein-Protein Interactions and Networks 8
between drug compounds and off-target proteins. Adverse drug reactions (ADRs) was
reported to be one of major causes of mortality and morbidity over the last decades [50].
Poly-pharmacology approaches have become popular in complementing the classical one-
drug one-target paradigm [51].
Still, the bottleneck of systematic screening of binding pockets for drug compounds in-silico
lays on the limited availability of experimental structures. Homology modelling can be
used in generating 3D protein models to compensate this limitation [52, 53]. However, high
quality structures are essential for binding pocket detection. Model refinement procedures
can help in obtaining a more realistic structure for these drug-target binding studies [54].
However, additional challenges in protein complex prediction are in that often proteins
are subject to conformational changes to attain specific binding modes. A special case is
when these functional states are induced by allosteric sites signalling, generally not easy
to observe experimentally [55]. Thus, conformational-change perturbations are usually not
taken into account in protein complexes modelling procedures.
In the following sections, we discuss the availability and quality of PPI datasets, as well
as the current state of high-throughput experimental methods for PPIs detection since
they are fundamental to build a 3D PPIN. We particularly focus on recent applications of
3D PPIN, highlighting strengths and discussing limitations related to the availability of
structural data for human proteins. Finally, we briefly comment on how 3D PPIN could
contribute to the design of novel targeted therapies, particularly useful to the advancement
of personalised medicine.
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1.2 Protein-Protein Interaction Data
High-throughput experimental methods have given the possibility to build PPINs of entire
organisms, which in some cases (e.g. yeast [56]) are deemed close to complete. They include
detection of direct interactions by yeast two-hybrid (Y2H) assays, and detection of protein
complexes by affinity purification-mass spectrometry (AP-MS). Literature curation and
annotation is another useful source for PPI datasets, often extracting information obtained
from small-scale experiments, such as Fluorescence Resonance Energy Transfer (FRET)
or other biophysical investigations. However, these collected datasets are usually biased
towards the proteins that have been most extensively studied and are not large-scale, due
to constraints in the detection methods. In 2008, it was estimated that about 650,000
PPIs should occur in humans [57] and so far about one-tenth of the estimated human
interactions have been observed experimentally [58]. Publicly available databases, such as
HPRD [59], BioGRID [60], DIP [61], IntAct [62], MINT [63], and STRING [64], provide
platforms to access PPIs curated datasets.
While the high-throughput experiment techniques are progressing to obtain complete pic-
tures of biological systems, low reproducibility of the data has raised concern about the
data quality. Braun P. [65] pointed out that the overlap of yeast PPI datasets derived from
AP-MS experiments between two labs could be as low as 20%. This may be ascribed to
different reasons, including the absence of the same standardised experiment protocols and
biased sampling. Varjosalo and colleagues [66] demonstrated that high-throughput PPI
experiments are highly reproducible when performed by two different labs if the protocols
with the same standardised workflows are used. Moreover, to diminish bias sampling, they
used 32 human kinases as bait proteins with a different domain composition, expressed in
different tissues and involved in different biological processes. Analogously, Havugimana
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and colleagues [67] generated a pipeline with stringent experiment procedures and apply-
ing computational methods to detect high-abundance components and identify functionally
unrelated protein pairs. Proteomic profiles were used to assess the abundance, reducing
the number of false positive interactions from protein pairs that in vivo are not expressed
at the same time and cellular space. Scientists in the AP-MS field are developing experi-
mental approaches to mitigate some of these inefficiencies, using, for example, replicated
and control experiments and relative quantification to enhance sensitivity and/or by de-
veloping confidence scores to select specific protein-protein interactions [68, 69, 70]. Apart
from experiment protocols, many studies also suggested the need of data standardisation
[71, 72] and validation [73, 68]. The International Molecular Exchange (IMEx) consor-
tium provides the controlled vocabularies and standardised data formats which have been
adopted by major databases [74, 75]. Statistical methods [76] and structural information
are also suggested for the validation of PPIs before they are deposited to the databases.
Additionally, a number of computational methods have been developed to compensate
the experimental methods and expand the space of PPINs based on strategies such as co-
evolution [77] and homology modelling [78] (for a recent review on computational predic-
tion methods see Mosca et al. [72]). However, high-confidence PPI data with experimental
evidence are fundamental to build 3D PPINs which could carry out more robust studies
in disease-related mutations and drug target identification.
1.3 Building 3D PPIN
As previously mentioned, PPIN is a useful tool in identifying disease or functional relation-
ships between proteins. Yet, system-level representations of biological processes provide
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very limited information on answering crucial questions, such as how a protein recognises
its partner proteins, or which region of its surface binds to its partner proteins. It requires
atomic level information to understand binding mechanisms. However, mapping struc-
tural information onto networks remains a challenge due to the gap between the number
of known proteins and the number of solved protein structures and some types of proteins
are under-represented in structure databases, such as membrane proteins. So far, the Pro-
tein Data Bank (PDB) [79] stores roughly around 5,000 human protein structures with
many of them containing only partial structures.
To tackle this problem, earlier work in developing 3D molecular interaction networks,
including iPfam [80] and 3did [81], analysed the structures of protein complexes at domain
level. The domain-based interactions are supported by both inter- and intra-species co-
crystal structures, and they include interactions between domains belonging both to the
same and to different proteins. 3did covers more than 4,000 distinct domains which is
about one-third of the total number of Pfam domains [82]. Importantly, domains are the
basic evolutionary and functional units of proteins. Proteins with domains in a common
superfamily are considered more likely to be evolutionarily related [83]. By looking at
molecular details of protein domain interactions, one could identify the domains which are
functionally important in mediating PPIs.
To increase the coverage of structures in PPINs, the two recent databases INstruct [25] and
Interactome3D [24] implement two different approaches both based on the use of homol-
ogous structures. One should be aware that PPI predictions using homologous structures
can be of different nature. One is to use homologous protein structures of a protein pair
to predict the possibility of interaction which is not detected from experimental methods.
The other is to predict structure complex of a protein pair which is known to interact from
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experimental methods and therefore trying to enrich with structural information in the
available large-scale screens. The following discussions are based on the second strategy to
predict the protein complexes. The pipeline of INstruct to generate a 3D PPIN starts from
binary interaction datasets from different publicly available databases. Each interacting
pair is then annotated with the corresponding co-crystal structure if available, or with
co-crystal structures of homologous proteins. It should be noted that the resulting struc-
tural annotation of protein pairs with homologous co-crystals is only approximate. The
database provides 3D PPIN data of human and six other most studied model organisms,
where human 3D PPIN contains 6,585 interactions between 3,627 proteins. A different
strategy was used for Interactome3D, where the structural coverage of human PPIN was
increased by modelling interacting pairs with missing structural data using Modeller [84].
This provides a more precise representation of interface regions of interacting protein pairs.
Interface residues are identified by calculating the distance of residues from protein pairs.
The database provides human 3D PPIN which contains 6,473 interactions between 4,239
proteins.
One may also use predicted protein structures obtained from reliable resources to compen-
sate the limitation of solved protein structures. A recent project Genome3D [85] integrates
UK-based structural resources, including Gene3D [86], FUGUE [87], and four other struc-
tural prediction resources [15, 88, 89, 90]. The aims of this project are to provide biologists
a platform to compare the predictions from those resources which were developed with dif-
ferent algorithms, and to choose the prediction outcomes which are more reliable. Those
predicted structures could help to expand the size of 3D PPINs.
To identify or even predict the proteins that can be acting together, one could use available
structural information. A study by Kar et al. [91] , for instance, looked at the structural
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features of cancer proteins. Cancer proteins are well known to involve biological processes
related to, for example, DNA repair and cell growth. In this study, ten functional path-
ways were selected according to the Cancer Cell Map (http://cancer.cellmap.org/cellmap).
Each protein pair in a given functional pathway is annotated with structural information
obtained by running PRISM [92], a software to explore the known protein-protein interface
binding modes and predict analogous cases. PRISM can predict the protein interaction
by searching interface with similar backbone geometry in the interface library. In this
way, co-crystal structures are not strictly required to build the PPIN of the pathway.
This method is beneficial for smaller scale studies with interests in proteins in particular
functional pathways and save computational time to construct a 3D PPIN of an entire
proteome.
To summarise, in this section we have reviewed some of the recent approaches to generate
3D PPINs. As it will be shown in the following sections, building increasingly complete
3D PPINs is essential to interpret biological systems, provide insight into complex cellular
mechanisms and rationalise genotype-to-phenotype relationships.
1.4 Protein Interaction Interfaces
The ability of proteins to recognise and bind their partners is essential to biological pro-
cesses. Protein interfaces, where proteins have physical contact with their partner pro-
teins, are believed to embed crucial properties which mediate PPIs. Both experiments and
computational analyses have shown that protein interfaces mediate PPIs through specific
molecular properties, including sequence motifs [47, 93], backbone geometry [94], residue
types [95], interface hot spots [34, 96], and correlated changes in the two interfaces.
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Precise atomic coordinates of protein complexes in 3D space are fundamental for studying
the physical and chemical properties of protein interfaces. The protein structure reposi-
tory Protein Data Bank [79] documents more than 90,000 protein structures in complexes
(data from April 2014) determined from different experimental observations, including X-
ray crystallography, Nuclear Magnetic Resonance (NMR), and electron microscopy. How-
ever, these crystal packings of molecular units may not always represent natural protein
interactions. Biological relevant interactions may be sacrificed in crystal state in order to
minimise global free energy. This could result in unspecific macromolecular interactions.
Hence, the atomic coordinate files in PDB database are classified as either biological as-
sembly or an asymmetric unit. The former represents the biologically-relevant complexes
which are either provided by the authors, validated using the software PISA [97], or both.
PISA calculates physicochemical properties of a micromolecular structure to estimate the
stability of the macromolecular complex. These properties include free energy of forma-
tion, gain in solvation energy, hydrogen bonds and saltbridges across the interface, and
hydrophobicity. The interfaces obtained from biological unit coordinate files are more
reliable to be the biological interface. The asymmetric assemblies contain either one bio-
logical assembly, a part of a biological assembly, or a combination of biological assemblies
depending on the crystallisation conditions for forming a crystal. Therefore, the interfaces
identified from the coordinate files of the asymmetric unit may not be protein functional
interfaces.
Each interface of a protein is comprised of several discontinuous patches. Two estimates
have been commonly used to define the interface regions. The first approach is to calcu-
late the distances between residue pairs from two proteins in a co-crystal structure [24,
44]. Two residues are considered as interacting if their distance is within a pre-defined
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threshold. This value may depend on the group of residue atoms that is used to calculate
the inter-residue distance. Typical threshold values are 4-5 A˚ on the distance between
any pair of atoms from the two residues [98, 81] or 9 A˚ on the distance between Cα or
Cβ atoms [44]. The sum of atomic van der Waals radii + 0.5 A˚ is another frequently used
distance threshold [99]. More sophisticated criteria use different thresholds for different
types of interactions (e.g. hydrogen bonds, salt bridges and van der Waals interactions)
[24]. The second approach compares the solvent accessible surface area (SASA) of the pro-
tein complex with that of the single components to evaluate the area buried upon complex
formation (interface area). For example, residues can be considered as part of the interface
if their total or side chain buried SASA is larger than 0-1 A˚2 [100, 101]. The calculation of
the buried area can be implemented in automated approaches such as POPSCOMP [102].
Pre-compiled values for PDB complexes are also available from databases such as 3did
and PIBASE [103]. For protein pairs where the structure of the single proteins is available
but not that of the complex, molecular docking methods, such as FiberDock [104], can be
used to predict the interface regions.
In one of the leading studies on biologic structural networks, Kim and colleagues [105],
classified hub proteins into two groups according to the number of their interfaces: multi-
interface hubs and singlish-interface hubs. The two groups were shown to have different
evolutionary properties. In particular, only multi-interface hubs turned out to be sig-
nificantly more essential and slow-evolving compared to the average. Since early studies
considered instead all hub proteins to be essential [106, 107], this shows that the integration
of sequential and structural information on protein interfaces can increase the precision in
identifying functionally important proteins within biological systems.
The importance of interfaces for protein functions and biological processes was further
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confirmed in recent studies by looking at the occurrences of disease-associated mutations
[27, 108], where interface regions were found to be enriched in disease-causing mutations.
This implies that a residue change at these region is more likely to disrupt protein functions
and lead to diseases. In a follow-up study by the same group [109], further annotations were
given to the mutations mapped on 3D PPIN. Dominant truncating disease mutations were
found to have different pattern to other classes of mutations with no preference occurring
at interface regions. Moreover, recessive mutations co-localised on the same interface,
showed the tendency to cause the same disease.
Increasing the level of detail in the description of protein interfaces further highlights the
importance of structural properties in determining the protein function. For example,
promiscuous binding sites, which are essential for hub proteins to interact with many
different partners, can be identified by mapping interactions with multiple partners on
the protein surface. Promiscuous sites have been shown to possess specific properties in
terms of amino acid composition [110, 111], solvent accessibility [112], packing [99] and
conformational flexibility [113, 114], mainly related with their increased capacity to adapt
to different partners. The biological relevance of promiscuous residues is further confirmed
by a recent study from our laboratory [113], showing that they are less enriched in nsSNVs.
This finding suggests that residues in promiscuous positions have a reduced tolerance to
genetic variations, related to the necessity to preserve their binding poly-valence.
Although key challenges remain in performing interactome-scale studies on protein inter-
face regions due to the low availability of protein structures, computational approaches
may help in overcoming this limitation. Gao and Skolnick [94] found that many protein
complexes have similar interfaces even if the overall structure of the single components
is different. Thus, they argued that even though there are only a small fraction of pro-
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teins with solved structures, the protein interface library is close-to-complete. This is the
fundamental idea behind protein binding pocket searches [115, 116] and PPI predictions
that use interface structure similarity scoring [78, 92] in order to increase the structural
coverage of 3D PPIN.
1.5 Molecular Properties of Interfaces
Based on complex composition, affinity and lifetime, protein complexes can be classi-
fied into different types: homo-oligomeric or hetero-oligomeric, non-obligate or obligate,
and transient or permanent complexes [117]. Protein interfaces play a role in molecu-
lar recognition and in determining the type of molecular interaction. Numerous studies
have explored the functional, evolutionary, and physicochemical properties of interfaces.
Identifying these properties is crucial for understanding not only how proteins determine
biological functions but also how disease-related mutations can disrupt cellular systems.
Early studies in characterising interface molecular features suggested that interfaces exhibit
distinctive features when compared to other parts of proteins. They are generally flat,
enriched with hydrophobic residues, most often forming part of helical secondary structures
[101], and containing a number of charged groups [118]. The residues at interfaces are
also more accessible than other solvent exposed residues and have fewer intra-molecular
contacts. More recent studies [119, 120] further examined and characterised interfaces of
different types of protein complexes, including homo-dimeric, hetero-dimeric and transient
protein complexes. Interfaces of heterocomplexes were found to be more planar and less
hydrophobic than homodimers. Whereas, transient complexes with smaller contact areas
are generally more conserved, planar and polar. Those with larger contact areas (>1000
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A˚2) often undergo conformational changes upon forming/breaking interactions [120].
1.6 How 3D PPINs Contribute to Biology and Biomedical
Sciences
Advances in genome sequencing techniques and large-scale genome sequencing projects,
including the 1000 Genomes Project [121] and the International HapMap Project [122], are
boosting the amount of available gene variation data. Databases, including dbSNP [123],
OMIM [124], COSMIC [125], HGMD [126], and Exome Variant Server (http://evs.gs.
washington.edu/EVS), provide online interfaces to easily access gene variation datasets
and serve with different purposes. The challenge is now to develop methods and tools to
extract useful information from this increasing amount of data. In particular, it will be es-
sential to understand what information those mutations are carrying, how we can use those
gene variation data to unravel the underlying cellular mechanisms, and how disease-causing
mutations lead to diseases [127, 28]. To answer these questions, atomic-level information
of protein complexes is crucial to provide the biological features of disease-related pro-
teins and disease-causing mutations. Moreover, by implementing large-scale studies with
3D PPINs, which contain information from system level to atomic level, one may find
explanations for the effects of these mutations. For example, Kar et al. [91] implemented
human structural protein interface network (iSPIN), in which the edges represent binding
interfaces between protein pairs obtained from either known or predicted structures from
PRISM. Their results show that cancer proteins tend to be hubs in the network. The mu-
tations occurring at cancer protein interfaces, disrupting protein bindings and causing loss
of protein functions, have greater impact on biological systems. The binding interfaces of
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cancer proteins were also shown to have specific properties; they are significantly smaller,
more planar, less compact and less hydrophobic than interfaces in non-cancer proteins.
These specific features of cancer protein interfaces may be used for the identification of
new targets and drug candidates in cancer therapies. The results demonstrated how 3D
PPINs can enable more comprehensive studies in biological systems with informative out-
comes. Besides, 3D PPINs can be effectively used in high-throughput screening for drug
targets. Indeed, PPIs are promising druggable targets since their selective inhibition [128]
can be used to regulate particular functions in biological systems. 3D PPINs, by represent-
ing in a synthetic and comprehensive way the associations between a target protein and
its partner proteins, are an invaluable tool to understand the possible effects of inhibiting
the binding interfaces of the target protein. All these examples show how 3D PPINs can
give an essential contribution to Biomedical Sciences.
1.7 Conclusions
The studies of PPINs have progressed from system level representations of biological sys-
tems to more detailed representations annotated with atomic information. The integration
of data from the currently available biological databases has proven to be essential to carry
out comprehensive studies on cellular mechanisms and the causes of their disruption. 3D
PPINs analysis has been used to study the role of disease-causing mutations. So far,
despite the general agreement on the propensity of disease-related mutations for protein
interface regions, the general characteristics of these mutations and how they affect bio-
logical functions remain challenging. Still, 3D PPINs analysis is very important to unravel
the features of these mutations and their impact on protein functions. In particular, the
identification of properties specific to pathogenic mutants is crucial to develop methods
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for the prediction of disease-related mutations. Besides, 3D PPINs analysis can also help
biologists to effectively search for possible targets for disease treatment as PPIs are ideal
drug targets [128] to regulate biological functions and the structural information in 3D
networks provides the guidance for the design of drug compounds in the early stage de-
velopment. 3D PPINs provide fundamental materials for the screening of off-target PPIs.
The use of these preliminary investigation strategies could effectively reduce time and cost
in drug development. The increased understanding of the pathogenic mechanisms trig-
gered by disease mutations, and of the activity of drug compounds in the cell, combined
with personal genome sequencing profiles, will promote the development and delivery of
more effective personalised clinical treatments in the foreseeable future.
The studies using 3D PPINs is a relatively new research field. The bottleneck in the
generation of complete 3D PPINs lays in the limitation of available experimental data
on genome sequences and protein structures. With the rapid progressing of experimental
technologies and bioinformatics approaches, more biological data will become available to
provide a more complete view of biological systems. In the coming years, the importance
of protein binding mechanisms and the general characteristics of disease mutations will
be better understood. Therefore, it will be possible to develop more sensitive predictors





Different types of genetic variations and their molecular effects on cellular functions will be
presented in this chapter. Recent advances in genome sequencing technology have largely
enriched the availability of human genome sequence data and enabled, numerous studies
on genotype-phenotype associations. The main source of the genome sequence data is large
consortia, and in particular, the 1000 Genomes Project [121], the international HapMap
Project [122], the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing
Project (ESP) (http://evs.gs.washington.edu/EVS/), and Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium [129]. Additionally, consortia
such as ENCODE Project [130] aim ambitiously to map the human genome landscape and
to outline the underlying functional elements, which span from coding and non-coding
transcripts to the marking of accessible chromatin and protein binding sites. Presently,
the main challenges in the field of genomic research are twofold: Firstly, seeking the rules
and patterns from this enormous and complex data archive, and secondly, understanding
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the underlying mechanisms linking genetic variability to specific phenotypic traits.
The majority of genetic variations are harmless and contribute to the differences between
individuals, while some of them can affect and alter cellular function using a variety
of mechanisms. Human genetic variants, including structural variations and Single Nu-
cleotide Variations (SNVs), have been intensively studied. The former refers to all genomic
changes that are not single nucleotide substitutions, including insertions/deletions (indels),
duplications, inversions, and Copy Number Variations (CNVs) [131]. The study of struc-
tural variations mainly focuses on the copy number variations which are often involved
in altering genomic structure and gene expression levels. Whereas, SNVs, being the most
ubiquitous form of genetic variations in human genome, have attracted a strong scientific
interest lately, with focus on the missense mutations that substitute amino acids on protein
sequences, as they can have a direct impact on protein structures and functions.
This chapter will present the current state of both experimental and computational meth-
ods related to the study of genetic variations. I will first introduce the different classes of
genetic variations, followed by a description of the methods implemented to identify the
variants in the human genome. The effects of genetic variations will also be discussed in
terms of their molecular impact on the cellular function.
2.2 Classes of Human Genetic Variation
Human genetic variants can be defined as common or rare by the Minor Allele Fre-
quency (MAF) in an observed population. Variants with MAF more than 5% are often
referred as common variants, whereas rare variants are defined as having a frequency of less
than 1% [132]. Genetic variants can also be broadly divided into SNVs and structural vari-
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ants. Structural variants includes insertions/deletions (indels), duplications, inversions,
and CNVs. The distinction between indels and CNVs is in the length of the variations.
The indels are generally defined as having a length of insertion, deletion, or duplication
less than 1kb, whereas CNVs are larger than 1kb [133]. Different types of genetic variants
have different roles in biological systems and can affect human health through disparate
mechanisms. Structural variants, for instance, have been suggested to be ubiquitous and
frequently related to the rearrangement of genes which alters the regulation of nearby
genes [134], while SNVs are the most common genetic variations between individuals and
are mostly neutral [135].
The classification of genetic variations is more complicated and difficult when looking at
cancer genomes. Cancer genetic variations can be classified as either driver, or passenger
mutations, according to their functional effect on proteins. Driver mutations provide a
selective growth advantage to the cancer cell, whilst, passenger mutations are present in
cancerous cells but do not promote growth [136]. Currently, to distinguish between these
two types of cancer mutations relies on experimental methods, which will be discussed in
the following section.
2.3 Detection of Disease-related Genetic Variations
It is commonly agreed that evolutionary forces influence genetic variation. The theory
of natural selection has raised many questions yet to be answered in modern biological
and biomedical science. Questions raised include the mechanisms of neutrally evolving
polymorphisms, the role of genetic variations in determining phenotypic traits, and the
properties and mechanisms of mutations which alter the fitness of humans.
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One classic example of human genetic studies is the immune resistance to malaria of the
sickle cell mutation carriers. Malaria was one of the major causes of mortality in human
history, and still is in certain part of the world [137, 138]. It has been suggested to be
the evolutionary driving force behind sickle cell anaemia disease, a recessive disease [139,
138]. People who carry the sickle cell allele at the human haemoglobin β locus have been
reported to have a higher chance of surviving malaria [140, 141]. In particular, the sickle
cell heterozygotes, who carry only one copy of sickle cell mutation, have even greater
resistance to malaria than the homozygotes [140]. The homozygotes, inherited from both
parents, also suffer sickle cell anaemia. This is an example of balanced polymorphism
where the individuals carrying both versions of a gene have better ability to survive or
adapt to the environment [142].
Studies that involve the detection of genetic variations for specific phenotypic traits require
genome sequence data for comparative analysis of genes between different populations,
most typically between patients and healthy individuals. Two commonly used experimen-
tal approaches to detect genetic variation include sequence-based and array-based. Human
genome sequence data of healthy individuals from the genome sequencing project, such as
the International HapMap Project, have often served as reference sequences to be com-
pared with the sequences of patients to identify and characterise the variants which are
responsible for the specific disease being analysed. Moreover, genomic microarray tech-
nology, has also been used to determine the genes or genetic variations that are associated
with specific diseases. Many genotyping arrays have been designed based on the HapMap
genome sequence data. The probes of the microarray allow for the effective detection of
indels and CNVs in the human genome and therefore are often used as a clinical diag-
nostic tool for the diseases that are caused by CNVs, such as autism disorders [143]. The
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downside of genomic microarray is that it heavily relies on frequency information from the
healthy control to reduce the background noise [134].
Genome-Wide Association Studies (GWAS) are the most widely used statistical approaches
to detect disease-related variants in large-scale. It is particularly effective in identifying
genes or variants that are associated with complex diseases such as diabetes, breast cancer
and prostate cancer. A growing numbers of novel loci have been identified and assessed
for statistical associations with specific diseases by GWAS over the last few years [144].
However, debates about GWAS methodology mean that the implementation and interpre-
tation of results should be done with caution particularly the selection of case and control
datasets (see [145] for more details on this topic), and the under-representation of rare
variants due to limited sample size [132]. The underlying mechanisms of the association
between genes and diseases remains largely unknown.
Many bioinformatics tools have been developed to predict the effects of exonic single point
variants which substitute amino acids on protein sequences: SIFT [146], PROVEAN [147],
PolyPhen2 [148], Panther [149], SNAP [150], i-Mutant [151] and many others. These pre-
diction tools utilise different approaches to measure the impact of variants on protein
functions. The most often used parameter in discriminating disease-related variants from
neutral variants is conservation scores because functionally important regions are generally
conserved. Some methods, such as PolyPhen2 and SNAP, increase the precision of the
prediction by including structural information, such as secondary structure prediction and
the physico-chemical properties of the involved residues. The method SAAP [152] fur-
ther mapped mutations onto structures to measure structural effects and predict resulting
phenotype of mutation using machine learning methods with a list of predefined features.
Other approaches, such as calculating ∆∆G values to measure the impact of the amino
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acid substitutions on the stability of the overall protein structures, are also used. Those
tools, mentioned above, often use the variation datasets obtained from UniProt, OMIM,
or dbSNP to train their methods. The prediction tools have reached fairly high accuracy
with germ-line disease variants [153].
Identifying cancer mutations, however, remains a challenge, particularly, the identification
of driver cancer mutations. These mutations have been suggested to play an important
role at the early development of cancer [136]. The identification requires many cancer
cell sequencing samples in order to detect highly mutated genes and recurrent variants.
To reduce the number of targeted genes and variants for further investigation, compu-
tational methods have been developed specifically for cancer driver mutations, including
MutationAssessor [154], MuSiC [155], CHASM [156], mCluster [157], CanPredict [158].
2.4 Molecular Mechanisms of Disease-related Mutations
Different types of disease-related mutations affect human fitness through a number of
possible mechanisms, most of these remain to be elucidated. Among those mutations,
CNVs and missense variants are currently the most studied mutation types, as they were
found to be the most common forms of disease-related variations.
CNVs have been shown indeed associated with many pathogenic phenotypes. Particularly,
they are often suggested to be involved in developmental disorders, including intellectual
disability (ID) and autism [159]. So far, CNVs have been reported to affect the amount
of gene expression by altering the numbers of genes in the genome or by occurring in the
gene regulatory elements to up-regulate or suppress gene expressions [160, 161, 162]. In
fact, the genome of healthy individuals would also contain several large size CNVs [163].
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However, the underlying mechanisms from the evolutionary point of view, in terms of their
actual functional pressure in the transformed genome remain to be discovered.
In contrast, SNVs are relatively well documented in many databases. Among different
types of SNVs, missense variants have been most studied due to the unique character-
istic that they can directly affect gene products by substituting amino acids in protein
sequences. In the following, and for the rest of the presented work, missense variants will
be referred as non-synonymous Single-Nucleotide Polymorphisms (nsSNPs).
The growing number of available crystal structures of protein complexes offers the unique
opportunity to study the structural features of nsSNPs. Many studies have shown that
drastic change of amino acids may destabilise or alter protein structures and function. One
example is shown in the study of patients with aldosterone synthase deficiency (ASD) type
I [164]. The mutation R374W in CYP11B2 protein causes the loss of hydrogen bonding
activity around residue R374. Hydrogen bonds is one of the most important elements
for protein stability. The mutation R374W consequently abolish enzyme activity of the
protein. nsSNPs can also affect biological systems by altering cellular interactions of the
mutated proteins. The aggregation of amyloid fibrils in neurodegenerative disease is a
classic example. The mutation D23N in amyloid β-protein was found to disrupt the local
structure of the protein and alter the hydrophobic core region to expose to the water phase
[165]. This consequently triggers the aggregation of amyloid β-proteins. The results from
recent studies [26, 27, 28, 29, 30] have also implied the importance of protein complexes
interface regions. Variants occurring at protein complex interface region are likely to be
associated with diseases. Moreover, genetic variations can affect protein function through
other mechanisms not directly occurring at ordered sites of protein complexes. Post-
translational modifications (PTMs), for instance, are often required for changing the state
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of proteins to perform specific functions. Mutations occurring at or close to PTMs may
result in a dysfunctional protein or keep the protein constitutively in a specific state.
Additionally, protein function can also be altered by mutations occurring at allosteric
sites. This consequently affect the communication pathways between the allosteric and
orthosteric sites, and modify the relative proportion of inactive/active conformations [36,
37].
2.5 Intrinsic Disorder
The focus of IDRs in this project is on the association between human mutations and
disordered structure regions and the features of the mutations occurring at these regions.
To fold globular-like compact structures had long been considered as the profound paradigm
for proteins to carry out their biological roles. It was only a decade ago, intrinsically disor-
dered proteins and Intrinsically Disordered Regions (IDRs) began to come to the attention.
Numerous proteins, particularly in Eukaryotes [166, 167], were found to be lacking a unique
fold, either partially or entirely, and play nevertheless essential roles in regulatory and sig-
nalling processes [167, 168]. In fact, proteins can exist in four different structure states: a)
compactly folded, b) compactly folded domain(s) with disordered regions (2.1), c) compact
but disordered, and d) extended intrinsically disorder. These can be grouped into three
broad states: ordered, collapsed (molten globule) and extended [169, 170, 171]. The differ-
ent structure states can undergo transitions from disordered to ordered upon binding to
their interaction partners [172]. The strong interest in IDRs lays with their sequential and
functional features, which includes the related sequence signatures, the biological roles,
binding mechanisms, their specific interaction partners, the association with diseases, and
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Figure 2.1: Partially intrinsically disordered structure - CD23 (PDB 1t8c) [173].
their involvement in druggable sites.
Thus far, IDRs have been studied mostly based upon the amino acid sequence informa-
tion, due to the fundamental constraints of experimental methods. In particular, crystal-
structure analysis requires stably folded-state structures for electron density quantifica-
tions. This has limited the available IDR structures [174]. To compensate for this limita-
tion, computational methods have been implemented to predict the disordered segments
on protein sequences. Boosted by the recognition of the IDR important biological roles,
more than 50 prediction tools are currently available, including MoRFpred [175], DISO-
PRED2 [176], PONDR-FIT [177], FoldIndex [178] amongst others (see [179] and [180]
for the comprehensive introductions of IDR prediction tools). The attributes adopted by
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those tools are based on the currently known biochemical properties of IDRs, often in-
cluding amino acid composition, hydrophobicity, secondary structure, solvent accessibility
and other physicochemical properties.
Although there has been significant progress in this area during the last decade, the follow-
ing properties of IDRs remain challenging to be fully understood. Firstly, the molecular
mechanisms of functioning for IDRs remain unclear. Current studies are mostly relying on
amino acid sequence information. The database ELM [181] provides known experimentally
validated motifs and a tool SLiM to identify putative linear motifs. The linear motifs are
composed of 3 to 11 contiguous amino acids and enriched in unstructured or disordered
regions of proteins. They often play an important role in regulating processes. These
documented short linear motifs could help to understand the molecular and sequence fea-
tures of functional segments at disordered regions. Just as ordered protein regions have
preferential physicochemical compositions of amino acids to form stable 3D structures,
disordered regions have also been reported to have compositional bias towards polar and
charged residues and to be lacking bulky hydrophobic ones [182, 183]. Still, this gives
very limited understanding of the association between the disordered structures and their
functional mechanisms.
Tools, such as MoRFpred, have been developed, using multiple sequence alignments, to
predict the functional segments on disordered regions called molecular recognition features
(MoRFs). However, these tools were trained and assessed with a very small number of
experimentally characterised disordered structure information. According to the database
DisProt release 6.02 (May 2013) [184], which documents currently known intrinsically
disordered proteins, only a total number of 694 disordered proteins and 1,539 disordered
regions have been recorded in the database.
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Moreover, different types of IDRs may exhibit different biochemical properties, adopt
different molecular mechanisms, and associate with different functions [185, 186]. One in-
teresting example is the HSP33 protein which undertakes ordered-to-disordered transition
as a defence mechanism to protect proteins from toxic aggregation and oxidative stress-
induced cell death [187]. This ordered-to-disordered transition differs from the commonly
known principle that IDRs are activated by post-translational modifications or phospho-
rylation and undertake disordered-to-ordered transition or remain disordered to determine
their functions. The variety of IDRs increases the level of difficulty in the predictions and
related studies.
The study of IDRs in the context of evolutionary conservation and implications for drug
design will not be discussed here as the focus of this project is on the human genetic
mutations. The occurrences of mutations at disordered regions that change the properties
mentioned above may have a dramatic impact on protein functions, such as the transition
between disordered and ordered states, and post-translational modifications. Thus far, no
systematic study has been presented for the role of IDRs in human mutation data and to
identify possible associations between IDRs and diseases. The computational methods do
not have sufficient sensitivity to predict the impact of mutations at disordered regions (see
chapter 3 section 3.4.7). This limitation is a result of the software being developed using
parameters which are based on the structural and sequence properties of protein ordered
regions. The diversity of disordered regions has also increased the level of difficulty in
predicting the impact of mutations at this region.
By identifying the common properties of disease-related mutations in disordered regions,
we hope to see if the common biochemical properties suggested by previous studies are
indeed essential in maintaining disordered structures and their functions. The mechanisms
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of determining biological functions and the impact of mutations at IDRs is presently
insufficiently documented and requires further exploration. A systematic study of human
disease-related mutation data at disordered regions will be presented in the next chapter.
2.6 Conclusions
Different types of genetic variations and their molecular effects on cellular functions were
presented in this chapter. Genome sequencing projects have improved our understanding
of genetic variations and their effects on cellular activity. However, the mechanisms of most
of the variations need to be further explored to complete our understanding of their impact
on diseased and healthy states. Sufficient biological data, including human genetic data,
structural and functional information enables more comprehensive studies on missense
mutations, particularly, for cancer mutations. Many computational methods have been
developed to predict the effects of germ-line disease mutations. The properties and the
underlying mechanisms of those variants needs to be better characterised. My work in the





Understanding how genetic variations contribute to phenotypic diversity and influence
individual’s fitness is of great interest in the field of biomedical research. Large-scale
genome sequencing projects, such as the 1000 Genomes Project [188], have been providing
an invaluable resource of human genetic variation data. Single-Nucleotide Polymorphisms
(SNPs) are the most prevalent form of genetic variations with an estimated occurrence in
the human genome of more than 11 million [132]. The majority of these are harmless and
neutral, and mainly responsible for subtle differences between individuals, including the
response to the environmental factors and the physical appearance.
In addition to the disease-related SNPs occurring at functional genomic regions, recent
studies have focused on single amino acid variants. These substitutions of amino acids are
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called missense variants or non-synonymous SNPs (nsSNPs) and can have a direct impact
on protein structures and ultimately alter protein function or disrupt the interaction with
partner proteins.
Statistical methods, such as genome-wide association studies, have been used to study
the patterns and frequencies of variants between different populations or species for the
purpose of identifying genes and variants that contribute to specific phenotype traits.
[189, 190, 191, 192]. However, the output of these studies requires further validation using
experimental methods, such as comparative analysis of hybridisation intensities on micro-
arrays [133], transgenic and knock-out methodologies [193]. Moreover, statistical analyses
associating variants and diseases provide limited information on the underlying biological
mechanisms that link variant occurrences to diseased cellular states.
Numerous computational methods have also been developed to predict the effects of nsS-
NPs on protein functions, such as PolyPhen2 [148], SIFT [146] and SNAP [150] amongst
others. Sequence conservation scores are commonly used as an attribute to predict the im-
pact of nsSNPs. Indeed, functionally important residues are generally conserved through-
out evolution and nsSNPs on sequence conserved regions are more likely to be deleterious.
PolyPhen2 and SNAP further include structural information, including structure-derived
constraints and physicochemical attributes of the variant changes, to predict the effects
of SNPs. In general, these methods have a moderate accuracy in distinguishing germ-line
disease SNPs from neutral SNPs. However, those prediction methods are comparatively
less sensitive and accurate for somatic cancer SNPs [194]. This may due to the fact that
cancer variants exhibit more diverse and variable properties than germ-line disease SNPs
and that these properties are not well characterised and defined as yet. By comparing
germ-line disease and somatic cancer SNPs at the atomic-level, we may find more sophis-
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Figure 3.1: Defined protein regions. Each protein in the human 3D PPIN is dissected
into four regions if possible. The domain region (structured region) includes surface,
interface, and core, while the disordered region is outside of the domain region and defined
by the predictor DISOPRED.
ticated features to distinguish the different types of disease-related variants. This would
be essential to develop more robust prediction methods, as well as to understand how
disease-related SNPs affect protein functions and lead to disease states.
3D PPINs have been successfully used in a number of recent studies to validate or predict
novel Protein-Protein Interactions (PPIs) [23], characterise protein binding interfaces [113,
112, 195], and study human mutations on protein structure complexes [27, 26, 108, 28].
Here we present a large scale study of disease-related nsSNPs using 3D PPINs. We built
up our own human 3D PPIN to maximise the number of 3D structures mapped onto the
available human interaction data. We aim at characterising the structural features (sur-
face, interface, core and disordered) of disease-related nsSNPs, including germ-line disease
nsSNPs and somatic cancer nsSNPs as obtained from the Online Mendelian Inheritance
in Man (OMIM) [124] and COSMIC [125] databases, respectively. The structural and
functional information in the constructed 3D network enables a more detailed insight into
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molecular features of disease-related nsSNPs. The selected nsSNPs were classified by their
occurrences in the defined protein region classes (surface, interface, core and inter-domain
disordered) (Figure 3.1), since nsSNPs in different classes can affect protein functions via
different mechanisms. SNPs occurring at the protein core, for instance, can alter or desta-
bilise the structure, while SNPs occurring in the proximity of a phosphorylation site at the
surface of a protein can possibly modify inactive/active conformation equilibria. Recent
examples of human genetic variation studies have reported the enrichment of disease-
related variants at protein interface regions, where proteins have physical contact with
other proteins [27, 26, 108, 28]. These genetic variations may disrupt protein functions by
altering the ability to bind to their partner proteins. The same enrichment was observed
in our collected disease-related nsSNP datasets (Figure 3.2).
In recent years the functional importance of protein disordered regions has come to notice,
so that they were included in our nsSNPs classification. Indeed, a large number of proteins
in eukaryotes have been found to be entirely or partially disordered [167, 168]. Disordered
regions can have a critical role in molecular recognition and protein binding. In particular,
they can undergo major structural changes upon binding to partner proteins [196] and
exhibit disorder to order transitions as those observed in Molecular Recognition Features
(MoRFs). Many studies on disordered regions have reported their essential role in cell
signalling and their implication in cancer [197, 198]. Their lack of a defined structure
raise a question about their tolerance to genetic variants and the underlying mechanisms
associated with disease. Therefore, the analysis of disordered regions included here can
give an insight into their molecular and functional features in comparison with structured
regions.
In the following, we will first analyse the distribution of different types of nsSNPs at dif-
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ferent protein regions (”3.2.1 Enrichment Analysis of Disease-related nsSNPs”). Then,
the relationship between nsSNPs occurrence and structural constraints will be investigated
(”3.2.2 Structural Features of Disease-related nsSNPs”). In particular, we will compare
the propensity of nsSNPs at flexible and stiff regions, as defined by their secondary struc-
ture annotations. Moreover, the relative frequency of drastic and moderate amino acid
changes induced by nsSNPs will be analysed. At last, the functional specificity of disease-
related nsSNPs (”3.2.3 Functional specificity of nsSNPs”) and their co-localisation on
protein interfaces (”3.2.4 Co-localised disease-related nsSNPs”) will be investigated.
3.2 Results and Discussion
An automated pipeline has been developed in this study to construct 3D PPINs (see
details in Chapter 4). The human 3D PPIN generated from the pipeline was composed of
8,249 proteins with 39,387 interactions. Each protein in the network was annotated with
structural and functional information. Two disease-related nsSNP datasets were obtained
from OMIM and COSMIC databases that document Germ-line Disease (GD) nsSNPs and
Somatic Cancer (SC) nsSNPs, respectively. In the following, GD nsSNPs will be referred
to as nsSNPsGD, while SC nsSNPs will be referred to as nsSNPsSC . A total of 12,761
nsSNPsGD and 202,719 nsSNPsSC were mapped onto the 3D network annotated with 3D
information. A control dataset was also obtained from dbSNP [123]. After filtering by
omitting known disease-related nsSNPs and mapping onto the 3D network, the control
dataset contains 461,674 nsSNPs with 3D information. This dataset is referred to as
common nsSNPs (nsSNPsC) in this study as it includes nsSNPs that are not known or
not yet known as disease-related.
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Surface Interface Core Disordered Mapped Unmapped
Common nsSNPs (nsSNPsC) 42,898 15,086 43,549 63,755 165,288 315,474
Mean(number of residues) ± SEM 126 ± 1.2 46.2 ± 0.5 135 ± 2.6 179.8 ± 3.2 - -
Germ-line disease nsSNPs (nsSNPsGD) 2,516 1,155 2,073 954 6,698 6,063
Mean(number of residues) ± SEM 157 ± 3.4 58.4 ± 1.5 186.2 ± 9.3 175.7 ± 8.6 - -
Somatic cancer nsSNPs (nsSNPsSC) 21,581 8,420 21,575 25,348 76,924 125,795
Mean(number of residues) ± SEM 127 ± 1.2 47 ± 0.5 140.4 ± 4.2 181.5 ± 3.2 - -
Table 3.1: Number of nsSNPs mapped on protein complexes of Human 3D
PPIN. The number of nsSNPs from each class and the average size (number of residues)
of the protein regions are listed. The standard error of the mean (SEM) is also reported.
The column ”Mapped” reports the total number of nsSNPs from each data group that
were mapped on the proteins of the 3D PPIN. The number of nsSNPs from each data
group that were not possible to be mapped on the human 3D PPIN is reported in the
column ”Unmapped”.
3.2.1 Enrichment Analysis of Disease-related nsSNPs
As mentioned previously, nsSNPs occurring at different protein regions can affect protein
structures and functions through different biological mechanisms. Therefore, each collected
nsSNP data group was classified into four classes according to the region of their occur-
rences and annotated as nsSNPssurface, nsSNPsinterface, nsSNPscore and nsSNPsdisordered
(see Methods ”Interface Identification”). The results obtained on nsSNP classes were com-
pared within each nsSNP data group with statistical tests. The number of nsSNPs in each
class and the average sizes of the regions are listed in Table 3.1. The enrichment of a given
nsSNP class in a protein region was measured by the abundance of the nsSNP class at
that region normalised by the overall abundance of the nsSNP class in the whole protein
(see Methods Formula 3.2).
As expected, the average size of interface regions is relatively small compared to the other
three regions. The interface regions were found enriched with disease-related nsSNPs
(nsSNPsGD) (Figure 3.2B) as previously reported [26, 27, 108]. One can observe a two-
fold enrichment in interface nsSNPsGD when compared to nsSNPsC (Table 3.2). Moreover,
nsSNPsSC were also found to be enriched by 20% (Figure 3.2C) compared to the control
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Figure 3.2: The enrichment of nsSNPs at different protein regions. (A) nsSNPsC
propensity. There is an enrichment of nsSNPsC at disordered regions. (B) nsSNPsGD
Propensity. (C) nsSNPsSC propensity. Both germ-line disease and somatic cancer nsSNPs
are enriched at the interface regions of proteins. Propensities are reported in logarithmic
scale. Error bars were estimated with bootstrap re-sampling with 10,000 replicates. Stars
are drawn to indicate the statistic significance levels (∗p < .05; ∗ ∗ p < .01; ∗ ∗ ∗p < .001)
of the comparison between interface and other region nsSNPs from pair-wise Wilcoxon
comparison tests.
(Table 3.2).
When comparing ordered (surface, interface and core) and disordered regions of proteins,
they are expected to differ in the tolerance to genetic variation, since ordered regions are
generally known to have more structural constraints in order to maintain the stability of
protein structures. Indeed, both nsSNPsGD and nsSNPsSC showed an overall enrichment
at protein ordered regions as previously documented [199], while common nsSNPs were
found significantly enriched at disordered regions. On the whole, only a small fraction of
nsSNPsdisordered was found to be related to disease. This supports our assumption that
disordered regions are more tolerant to the occurrence of nsSNPs than ordered protein
regions.
In this study, the same enrichment analyses were performed on the nsSNPs’ functional
specificity and structural constraints. The results section is presented as follows. Firstly,
the correlation between structural flexibility and tolerance to genetic variations will be
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Surface Interface Core Disordered
nsSNPsGD 1.48 1.91 1.09 0.48
nsSNPsSC 1.1 1.22 1.05 0.87
Table 3.2: Fold change of disease SNPs dataset. A value less than one indicates a
negative fold change (e.g. a value of 0.5 indicates a drop of 50% from the control and is
reported as -2 fold change). Both nsSNPsGD and nsSNPsSC were found to be enriched at
protein ordered region with respect to the control SNP data, while negative fold changes
were observed at disordered regions.
measured by calculating the enrichment of nsSNPs on the secondary structure elements of
each protein. The properties of the nsSNPs will also be analysed relative to the transitions
of amino acid types and compared between four pre-defined classes of nsSNPs (see Meth-
ods) and compared between nsSNP datasets. Secondly, the likelihood of nsSNPsGD and
nsSNPsSC affecting protein function by occurring at functionally important positions will
be measured by screening nsSNPs that are at or close to protein functional sites and Post-
Translational Modification (PTM) sites in the structural 3D space. Finally, we will further
investigate the enrichment of nsSNPsGD and nsSNPsSC at interface regions by measuring
the frequency of interface co-localisation for disease-related nsSNP pairs involved in the
same type of disease. The functional similarity of interaction protein pairs will also be
measured. In particular, the pairs that are involved in the same disease will be compared
with the pairs related to different diseases and non-disease-related pairs.
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Figure 3.3: Distributions of re-sampled SNP propensities. The first four columns
show the distributions of the SNP propensities relative to four protein regions, while the
plots in the last column show the propensities at all four protein regions. The top three
rows are the propensities of nsSNPsC , nsSNPsGD and nsSNPsSC , respectively, at different
protein regions. The plots in the last row show the distributions of the three SNP datasets
at different protein regions.
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3.2.2 Structural Features of Disease-related nsSNPs
The relationship between structural constraints and the abundance of disease-related nsS-
NPs at protein ordered regions (surface, interface, core) was investigated and compared
within each nsSNPsC , nsSNPsGD and nsSNPsSC dataset. This analysis was performed by
comparing the propensity of nsSNPs to occur at regions with different secondary structure
elements. This has commonly used by computational prediction methods as a parameter
to evaluate the effect of amino acid substitutions.
Based on the secondary structure definition from DSSP [200], each class at ordered region
was further divided into stiff and flexible structural segments (Figure 3.4A). The stiff
segments include helix and strand, while loop and turn are classified as flexible segments
(see ”3.4.5 nsSNPs at Secondary Structure Elements”). A summary of collected nsSNPs
in each secondary structure segment, protein region, and nsSNP data group is given in
Table A.1.
The stiff segments of proteins are generally considered to be less tolerant to mutations
than the flexible segments. In general, nsSNPsC are under-represented in the structured
regions of proteins, apart from surface flexible segments which were found to have a higher
propensity of nsSNPsC (Figure 3.4B). nsSNPsC were found mostly occurring at disordered
regions as reported in the previous section (Figure 3.2).
In comparison, both nsSNPsGD and nsSNPsSC were found to be enriched at ordered
regions rather than disordered regions. nsSNPsGD were observed at comparatively higher
propensities at the stiff secondary structure elements in the solvent exposed area (including
both surface and interface regions of isolated proteins) than the flexible elements (Figure
3.4C, purple bars: nsSNPsGD stiff segments; green bars: nsSNPsGD in flexible segments).
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nsSNPsGD were enriched by more than two-fold at the interface stiff segments compared
to the control (Table 3.3). These nsSNPs may affect protein functions either by altering
the structure at the exposed area or by affecting critical functional sites, which will be
further discussed in the next section.
nsSNPsGD at core regions were found to be enriched at flexible segments (Figure 3.4C,
green bars and green-coloured secondary structure in Figure3.4A). This may relate to the
fact that the structure composition at a protein core region is often critical to maintain the
stability of the protein. The occurrences of nsSNPsGD at the flexible segments of the core
may have an impact on protein function and stability but are not as critical as nsSNPsGD
at the stiff segments.
Whereas, nsSNPsSC were found less enriched at stiff segments for all the considered classes
of nsSNPs (Figure 3.5). nsSNPsSC showed less differences in secondary segment prefer-
ences at surface regions (Figure 3.5). When compare with nsSNPsC , the nsSNPsSC are
enriched by 26% at the interface flexible regions (Table 3.3).
These results may suggest that nsSNPsGD and nsSNPsSC exhibit different physicochemical
properties and adopt different mechanisms to affect protein structures and functions. To
further assess this hypothesis, this analysis was followed by a more detailed investigation
at the residue level by calculating the frequencies of amino acid type changes relative to
each class of nsSNPs.
Each amino acid exhibits different characteristics in terms of size, charge, hydrophobic-
ity, polarity and other physicochemical features. An event of residue substitution can be
classified as a drastic or moderate change based on the similarity between the two amino
acids. A drastic change, such as the change from a positively charged residue to a nega-
tively charged residue, is more likely to have greater impact on the stability of the protein
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structure than a moderate change from a positively charged to a polar residue (scheme in
Figure 3.6).
The frequency of nsSNPsGD and nsSNPsSC in each drastic and moderate change sub group
was calculated and compared with neutral mutation nsSNPsC . In general, nsSNPsGD
and nsSNPsSC showed a higher frequency for most of drastic change sub groups com-
pared to nsSNPsC (Figure 3.7 orange bars: nsSNPsC ; blue bars: nsSNPsGD; green
bars:nsSNPsSC). In particular, nsSNPsGD were found with comparatively higher fre-
quency in drastic changes and lower frequency in moderate changes (Figure 3.7, blue
bars).
The frequency of drastic and moderate changes induced by ordered-region nsSNPs (surface,
interface, and core) were also calculated relative to the secondary structure elements.
Interestingly, drastic substitutions induced by nsSNPsGD showed a higher abundance in
stiff structure segments over three classes of nsSNPsGD (Figure 3.8, blue bars). On the
other side, each class of nsSNPsSC (Figure 3.8, green bars) showed a pattern similar to
neutral mutation nsSNPsC (Figure 3.8, orange bars).
In summary, these results show that nsSNPsGD exhibit features that are consistent and
distinguishable from nsSNPsC in terms of structural preferences and trends in physic-
ochemical changes. Whereas, nsSNPsSC have higher enrichment at flexible structural
segments and with milder physicochemical changes. However, nsSNPSC dataset contains
not only the driver variants but also additional passenger variants. The passenger muta-
tions are found in the cancer genome but do not contribute directly to the development of
cancer. The results obtained from nsSNPsSC dataset may be partially ascribed to cancer
passenger variants. This could explain the similar feature of the nsSNPsSC to the control.
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Figure 3.4: nsSNPs associations with protein stiff and flexible structure re-
gions. (A) Stiff (purple) and flexible (green) structure regions. The stiff regions of proteins
include helix and strand, while flexible regions include loops and turns. (B-D) The propen-
sities of different nsSNPs (nsSNPsC , nsSNPsGD and nsSNPsSC) relative to stiff (purple)
and flexible (green) structure regions. The greater the value, the stronger the association
with the type of the secondary structure. Propensities are reported in logarithmic scale.
Error bars were estimated with bootstrap re-sampling with 10,000 replicates. Stars are
drawn to indicate the statistic significance levels (∗p < .05; ∗∗p < .01; ∗∗∗p < .001) of the
comparison between stiff and flexible region nsSNPs from pair-wise Wilcoxon comparison
tests. A summary of nsSNPs in different classes of stiff/flexible regions is given in Table
A.1.
Surfacestiff Surfaceflexible Interfacestiff Interfaceflexible Corestiff Coreflexible
nsSNPsGD 1.55 1.4 2.03 1.78 1.01 1.43
nsSNPsSC 1.1 1.09 1.19 1.26 1.03 1.14
Table 3.3: Fold change of disease SNPs dataset at stiff and flexible structure
regions. A value less than one indicates a negative fold change.
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Figure 3.5: Distributions of re-sampled SNP propensities. The columns show
the distributions of the SNP propensities relative to protein surface, interface and core
regions. The top three rows are the propensities of nsSNPsC , nsSNPsGD and nsSNPsSC ,
respectively, at different protein regions. The plots in the last row show the distributions
of the three SNP datasets at different protein regions.
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Figure 3.6: Scheme of drastic and moderate amino acid type changes in nsS-
NPs. Drastic changes (red) include changes between non-polar and negatively charged,
non-polar and positively charged, positively charged and negatively charged residues, and
any residues change to or from proline. Whereas moderate changes (light blue) include
changes between non-polar and polar, polar and negatively charged, polar and positively
charged residues, together with changes within each residue class.
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3.2.3 Functional Specificity of nsSNPs
Apart from having impact on the stability of protein structures, nsSNPs can also affect
protein function through the substitution of functional residues. One example is given
by the mutations occurring at protein IDH1 active site. IDH genes encode isocitate de-
hydrogenase cytoplasmic with the function of catalysing the conversion of isocitrate into
α-ketoglutarate [201]. The substitution of an arginine residue at the active site with a
different amino acid alters the enzymatic activity of the protein, which consequently el-
evates the level of R−-2-hydroxyglutarate. This was found to be an important factor to
promote the cancer progression of Glioblastoma multiforme [202]. Therefore, to elucidate
the molecular features that affect protein function at SNP sites, the occurrences of nsS-
NPs at functional residues have been examined at both sequence and molecular level.
The propensity of nsSNPs to occur at functionally important residue positions have been
calculated for each nsSNP class. The annotations of functionally important sites, such
as active sites, binding sites, metal binding, PTM sites, were obtained from the UniProt
[203] and PTMcode [204] databases. A total of 2,100 and 4,370 proteins in the human 3D
PPIN were annotated with functional sites and PTM sites, respectively. The PTM site
analysis will be studied independently as they exhibit molecular characteristics different
from other functional residues.
A screening of nsSNPs occurring at the exact positions of functionally important residues
was first implemented. Only a small number of proteins in the 3D human PPIN were found
to have nsSNPs occurring at functional residue positions (see Table A.3 and Table A.4
section A). One likely explanation is that the occurrences of nsSNPs at the functionally
important residue positions is more likely to be lethal for the mutant-carrying organism.
Therefore, this type of mutations is not fixed in the population.
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Figure 3.9: Screening SNPs close to functional sites in 3D. Residues spatially
close to a given functional site (stick representation coloured in red) were selected using
a 8A˚ threshold on Cα atoms. The residues shown in stick representation and coloured in
blue are the residues detected to be close to the considered functional site.
Moreover, the occurrence of nsSNPs close to functionally critical residues can also have an
impact on protein function. The V600E mutant of B-RAF, for instance, has been found
in many human cancers. The mutation, adjacent to the phosphorylation sites Thr598 and
Ser601, affects the cell by stimulating B-RAF kinase activity and consequently increasing
ERK signalling [205]. Therefore, spatially proximate residues to functional residues should
also be taken into account in the implementation of the screening.
The screening of nsSNPs close to functionally important residues was implemented both
at the structural level (Figure 3.9) and at the sequence level. The screening of spatially
close residues requires protein structure information and thus was implemented only for
the nsSNPs occurring at ordered protein regions, including surface, interface and core.
Residues spatially close to a given functional site were selected using a 8A˚ threshold on Cα
atoms (Methods). The sequence-based screening was performed using a screening window
of 5 residues. Only the sequence-based screening was used to measure the enrichment
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of disordered region nsSNPs that are close to functional residues and to perform the
comparison between ordered (surface, interface and core) and disordered regions. The
number of nsSNPs that were found to be close to functionally important residues is listed
in Table A.3 and Table A.4. Expectedly, the structure-based method detected a higher
number of close-to-functional-site nsSNPs (Table A.3C) than the sequence-based method.
Moreover, the results from the structure-based screening method showed a slightly different
patten for nsSNPsGD group, where the comparative enrichment is more evident for surface
nsSNPsGD (Figure 3.10B and E).
The propensities of nsSNPs relative to protein regions were calculated and compared
within each nsSNP data group (nsSNPsC , nsSNPsGD and nsSNPsSC) Figure 3.10. The
propensities calculated for different nsSNP classes in all SNP groups indicates that nsSNPs
are generally not favoured to be close to functional residues (propensities are smaller
than 1). However, by comparing nsSNPsGD and nsSNPsSC to nsSNPsC data group, both
sequence-based and structure-based screening methods detected a comparative enrichment
of close-to-functional-site nsSNPs for both disease nsSNP groups. nsSNPsGD showed more
than two-fold enrichment for all the ordered protein regions compared to nsSNPsC (Table
3.4). Whereas, the nsSNPs at disordered regions were found to have the lowest frequency
in the region close to functional sites in all three nsSNP data groups (Figure 3.10A, B and
C and Figure 3.11).
When looking at close-to-PTM-site nsSNPs, all SNP data groups were also found with
no preference to be close to PTM sites (propensities are smaller than 1). However, both
sequence-based and structure-based screening methods revealed a comparative enrichment
for both disease nsSNPsGD and nsSNPsSC data group in comparison to nsSNPsC . In par-
ticular, nsSNPsGD and nsSNPsSC at interface regions were found more evidently enriched
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(Figure 3.13) by a factor of 2 compared to the control (Table 3.5). Whereas, the disordered
regions were found to contain a high number of nsSNPsC but they were less abundant in
nsSNPsGD and nsSNPsSC compared with interface regions (Figure 3.14).
To summarise these results, we found that nsSNPs are generally not favoured to be close
to functionally important residues. This probably due to the fact that the occurrences
of mutations at/close to those functional residues are more likely to lethal. Only by
comparing the disease nsSNPsGD and nsSNPsSC data groups to nsSNPsC , a comparative
enrichment was found in disease nsSNP groups over all nsSNP classes. In particular, both
nsSNPsGD and nsSNPsSC at the solvent-exposed surface area of proteins (surface and
interface regions) have a significantly higher tendency to be close to functionally important
residues (functional sites and PTMs) than those nsSNPs at the core of proteins. The close-
to-PTM-site nsSNPs also showed a larger propensity at disordered regions in general.
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Figure 3.10: nsSNPs close to protein functional sites. Propensities of nsSNPs,
which are at or close to functional sites, were calculated over surface (coral), interface
(green), core (yellow) and disordered (grey) regions. Error bars were estimated with
bootstrap re-sampling with 10,000 replicates. Stars are drawn to indicate the statistic
significance levels (∗p < .05; ∗ ∗ p < .01; ∗ ∗ ∗p < .001) of the comparison between interface
nsSNPs and other nsSNP classes from pair-wise Wilcoxon comparison tests. (A)-(C)
Close-to-functional-site nsSNPs identified by a sequence-based screening method with a
window of 5 residues. (D)-(F) Close-to-functional-site nsSNPs identified by structure-
based screening method with a 8 A˚ threshold. (A) and (D) nsSNPsC propensity. (B)
and (E) nsSNPsGD propensity. (C) and (F) nsSNPsSC propensity. Interface nsSNPs
are comparatively enriched at the segments close to functional sites from both screening
methods in the three nsSNP data groups. A summary of detected nsSNPs using both
methods is given in Table A.3.
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Surface Interface Core
nsSNPsGD 3.11 2.69 2.23
nsSNPsSC 1.2 1.4 1.13
Table 3.4: Fold change of close-to-functional-site SNPs (3D). A value less than one
indicates a negative fold change. Both nsSNPsGD and nsSNPsSC show higher enrichment
compared with the control SNP data.
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Figure 3.11: Distributions of re-sampled close-to-functional-site SNP propen-
sities. The first four columns show the distributions of the close-to-functional-site SNP
propensities relative to four protein regions, while the plots in the last column show the
propensities at all four protein regions. The top three rows are the propensities of nsSNPsC ,
nsSNPsGD and nsSNPsSC , respectively, at different protein regions. The plots in the last
row show the distributions of the three SNP datasets at different protein regions.
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Figure 3.12: Distributions of re-sampled close-to-functional-site SNP propen-
sities (in 3D space). The first three columns show the distributions of the close-to-
functional-site SNP propensities relative to protein surface, interface and core regions,
while the plots in the last column show the propensities at all three protein regions. The
top three rows are the propensities of nsSNPsC , nsSNPsGD and nsSNPsSC , respectively,
at different protein regions. The plots in the last row show the distributions of the three
SNP datasets at different protein regions.
Chapter 3. Computational Analyses of Disease-related Variants 58
Figure 3.13: Close to protein PTM site nsSNPs. Propensities calculated over
Surface (coral), Interface (green), Core (yellow) and Disordered region (grey) nsSNPs that
are at or close to PTM sites. Error bars were estimated with bootstrap re-sampling with
10,000 replicates. Stars are drawn to indicate the statistic significance levels (∗p < .05; ∗ ∗
p < .01; ∗∗∗p < .001) of the comparison between interface nsSNPs and other nsSNP classes
from pair-wise Wilcoxon comparison tests. (A)-(C) Close-to-PTM-site nsSNPs identified
by sequence-based screening method with a window of 5 residues. (D)-(F) Close-to-PTM-
site nsSNPs identified by structure-based screening method with a 8 A˚ threshold. (A)
and (D) nsSNPsC propensity. (B) and (E) nsSNPsGD propensity. (C) and (F) nsSNPsSC
propensity. Interface nsSNPs are comparatively enriched at the segments close to PTM
sites from both screening methods in the three nsSNP data group. Disordered regions were
also found with a larger propensity in close-to-PTM-site nsSNPs. A summary of detected
nsSNPs using both methods is given in Table A.4.
Chapter 3. Computational Analyses of Disease-related Variants 59
Surface Interface Core
nsSNPsGD 2.53 2.71 2.46
nsSNPsSC 1.29 1.63 1.29
Table 3.5: Fold change of close-to-PTM-site SNPs (3D). A value less than one
indicates a negative fold change. Both nsSNPsGD and nsSNPsSC were found with higher
enrichment compared with the control SNP data.
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Figure 3.14: Distributions of re-sampled close-to-PTM-site SNP propensities.
The first four columns show the distributions of the close-to-PTM-site SNP propensities
relative to four protein regions, while the plots in the last column show the propensities at
all four protein regions. The top three rows are the propensities of nsSNPsC , nsSNPsGD
and nsSNPsSC , respectively, at different protein regions. The plots in the last row show
the distributions of the three SNP datasets at different protein regions.
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Figure 3.15: Distributions of re-sampled close-to-PTM-site SNP propensities
(in 3D space). The first three columns show the distributions of the close-to-PTM-site
SNP propensities relative to protein surface, interface and core regions, while the plots in
the last column show the propensities at all three protein regions. The top three rows are
the propensities of nsSNPsC , nsSNPsGD and nsSNPsSC , respectively, at different protein
regions. The plots in the last row show the distributions of the three SNP datasets at
different protein regions.
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3.2.4 Co-localised Disease-related nsSNPs
A previous study [109] elucidated interface co-localised mutations and demonstrated that
recessive mutations co-localised on interface of a protein interaction pair have the tendency
to cause the same disease. This observation can be explained by the fact that interacting
proteins often perform similar biological functions and are involved in the same biological
process. However, it is not known why the tendency to interface co-localisation of muta-
tions related to the same disease is observed only for recessive and not for the dominant
mutations.
In the study presented here, a different approach was applied to study interface co-localised
nsSNPs. First, disease-related nsSNPs (nsSNPsGD) were classified with the associated
disease types obtained from Goh et al. [10] (see Methods). nsSNPsSC were classified by
the primary cancer tumour type. The list of disease types and the number of nsSNPs
corresponding to each each disease type are shown in Table A.5 and A.6.
Second, the interface co-localised nsSNPs, which share the interfaces with other disease-
related nsSNPs, were further divided into three classes: inter-interface specific (nsSNPsS Inter),
intra-interface specific (nsSNPsS Intra) and others (nsSNPsMulti). A nsSNPS Inter is de-
fined when the nsSNP is found to cause the same type of disease as another nsSNP on the
opposing side of the interface as shown in Figure 3.16A. A nsSNPS Intra is a SNP that is
found to cause the same type of disease as another nsSNP which is co-localised at the same
interface as shown in Figure 3.16B. The interface disease-related nsSNPs which do not fit
into these two definitions are classified as nsSNPsMulti. The implementation of screening
and classifying interface nsSNP is presented in Methods ”3.4.11 Classification of Interface
nsSNP”. The propensities of the interface classes of nsSNPsGD and nsSNPsSC datasets
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were calculated and compared using statistic assessment (see Methods).
The comparison of different classes of interface nsSNPsGD showed that the nsSNPsS Intra
were significantly more abundant among interface nsSNPsGD (Figure 3.16C). This may
suggest that the causes of germ-line diseases are more likely related to the structural or
functional alteration of a single protein or a group of proteins. It may take evolutionary
times to accept two substitutions, possibly aided by other compensatory substitutions
that were not monitored here. The co-localised nsSNPsGD of a specific protein do not
necessarily occur at the same time but they can disrupt the protein function through the
same mechanism by altering the same binding interface. The nsSNPsSC group showed
instead a reduced propensity for either inter- or intra-interface co-localisation (Figure
3.16D)
A possible explanation of interface co-localisation for nsSNPsGD is that disease types
are correlated with protein functions. To assess this hypothesis, the functional similarity
between the affected interaction protein pairs was measured. Each protein in the 3D PPIN
was annotated with disease types extracted from their relative disease-related nsSNPs.
According to the disease types of protein pairs, the interaction pairs were divided into three
classes, including the PPIs that are involved in the same disease (PPIsdisease), involved
in different diseases (PPIsdiff ) and that are non-disease related (PPIsnon). Each protein
was annotated with Gene Ontology (GO) term annotations (biological process). The
functional similarity of the interacting protein pairs over these three classes of PPIs was
measured using the Total Ancestry Similarity (TAS) method and compared (Methods).
The association between the resulting disease types and the protein functions was measured
by the tendency of nsSNP co-localisation and the functional similarity of the interaction
proteins. The lower the TAS score, the higher the similarity between a protein pair.
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Our results showed that PPIsGDdisease got significantly lower TAS score than PPIs
GD
diff and
non-disease PPIs (Figure 3.17A). This indicates that PPIsGDdisease have high functional simi-
larity between interaction protein pair, while PPIsGDdiff showed the lowest functional similar-
ity. Based on this observation, we may argue that for germ-line diseases, protein functions
are an important factor to relate a nsSNP to a specific disease. Moreover, the results in
the previous sections indeed showed that nsSNPsGD affect protein functions dominantly
by their direct impact on functionally important sites. Those nsSNPs are mutations that
interfere with protein functions but are not lethal and transmitted through generations.
Moreover, to support our argument that protein function play a crucial role in determining
the associated disease types of nsSNPs, protein domains were also annotated with domain
functions using SCOP superfamily functional annotations (Methods). By measuring the
frequency of nsSNPsGD related to SCOP [206] domain functions, the associated disease
types were found to be related to the functions of the affected proteins (Figure 3.18). For
example, a large number of nsSNPs occurring at domains with the SCOP domain function
”Metabolism” are associated with Haematological disease.
On the other hand, nsSNPSC proteins showed a very different pattern, where PPIsSCdisease
were found to have the lowest functional similarity compared to the rest (Figure 3.17B).
This may highlight the fundamental differences between germ-line diseases and somatic
cancers, in that the progress of cancer is often suggested to involve multiple mutation
events [207].
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Figure 3.16: Interface co-localised disease-related nsSNPs. (A) Inter-interface
specific nsSNPs. Interface nsSNP pairs (residues shown in sphere representation and
coloured in red) locate on opposing side of interface of interacting proteins A and B.
(B) Intra-interface specific nsSNPs. Interface nsSNPs pairs locate on the same side of
the interface. Interface nsSNPs were divided as S Inter, S Intra and Multi. S Inter and
S Intra indicate the nsSNPs shown in (A) and (B), respectively. Interface nsSNPs that
do not pair with other nsSNPs related to the same diseases are defined as Multi. (C) and
(D) are the propensity of each type of interface nsSNPsGD and nsSNPsSC respectively.
Propensities are reported in logarithmic scale. Error bars were estimated with bootstrap
re-sampling with 10,000 replicates. Stars are drawn to indicate the statistic significance
levels (∗p < .05; ∗ ∗ p < .01; ∗ ∗ ∗p < .001) of the comparison between three classes of
interface nsSNPs from pair-wise Wilcoxon comparison tests.
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Figure 3.17: Functional similarity of interaction protein pairs. PPIsdisease indi-
cates PPIs that are involved in the same disease and labelled as ”Same Disease”. PPIsdiff
indicates PPIs that are involved in the different disease and labelled as ”Different Dis-
ease”. PPIsnon indicates non-disease related protein pairs and labelled as ”non-Disease”.
(A) The functional similarity of germ-line disease protein interaction pairs. (B) The func-
tional similarity of somatic cancer protein interaction pairs. Stars are drawn to indicate
the statistic significance levels (∗p < .05; ∗ ∗ p < .01; ∗ ∗ ∗p < .001) of the comparison
between different interface nsSNPs groups from pair-wise Wilcoxon comparison tests.
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Figure 3.18: Numbers of nsSNPsGD relative to domain functions and the types
of diseases. The x axis indicates the SCOP functional categories of domains [206].
nsSNPsGD were assigned to the functional categories of their occurring domains. The
nsSNPsGD in each category were further divided by their associated disease types, which
are shown in the y axis. The disease categories were obtained from the annotation of Goh
et al.[10]. The z axis indicates the count of nsSNPsGD in each functional category and the
disease type.
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3.2.5 Prediction of nsSNP Impact
Current prediction methods, such as PolyPhen2, often use both sequence and structure
information to predict the impact of SNPs on protein function. PolyPhen2 was used to
predict the impact of nsSNPs in three SNP datasets: nsSNPsC , nsSNPsGD and nsSNPsSC .
Apart from disordered region nsSNPs, PolyPhen2 performs with fairly good accuracy in
germ-line disease SNP predictions, where interface nsSNPsGD got the highest score.
As expected, a larger number of nsSNPsSC were predicted to be ”neutral” and in many
cases PolyPhen2 was unable to predict the effect of nsSNPsSC . The reasons are that,
firstly, the prediction tool was designed for and trained with germ-line mutation SNPs.
Moreover, somatic cancer SNPs exhibit structural and functional properties that are rather
different from germ-line disease SNPs, as the results in the previous sections have shown.
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3.3 Conclusions
In this study we looked at the structural and functional features of germ-line disease
nsSNPs and somatic cancer nsSNPs to assess their roles on protein function. Our results
suggest different behaviours of these two types of disease-related nsSNPs. The nsSNPsSC
were found to be enriched at flexible secondary structural elements of proteins and they
preferentially locate close to functionally important sites. On the other hand germ-line
disease nsSNPs are preferentially located at structurally stiff region and affect protein
functions when drastic amino acid changes are fixed in the genome. These results sketch
the different constraints acting on these two types of disease-related nsSNPs and the
associated disease-causing likelihoods. Moreover, germ-line diseases were found to be
highly correlated to the functions of nsSNP-affected proteins. Overall, somatic cancer
SNPs were found to exhibit fundamentally different characteristics from germ-line disease
SNPs in terms of physicochemical properties and functional specificity. Our study has
demonstrated an effective method to characterise disease-related nsSNPs by integrating
structural and functional information.
3.4 Materials and Methods
3.4.1 The human 3D Protein-Protein Interaction Network
The human PPI dataset was generated using six publicly available databases, including
BioGRID [60], DIP [61], HPRD [59], IntAct [62], MINT [63] and STRING [64]. The dataset
from Havugimana et al. [67], which contains novel PPIs derived from AP-MS experiments,
was also obtained and integrated with the other six PPI datasets. The UniProt [203] ac-
cession identifier was used as the reference identifier of the proteins in the network. The
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mapping between UniProt accession identifiers and other protein identifiers was based on
the mapping provided by UniProt, which was downloaded from the UniProt FTP repos-
itory. Having removed duplicated interactions, our human PPI dataset contains 18,399
proteins with 1,878,098 interactions. Each protein was then annotated with the relative
Pfam[82] domains. Solved or homologous structures of protein domains were identified
running PSI-BLAST v.2.2.26+ [208] against the PDB [79]. Homologous structures were
selected when they have more than 80% coverage of a protein domain with over 30%se-
quence identity. The interaction protein pairs retained in the network had to fulfil the
following criteria:
1. An interaction protein pair is constituted of both human proteins.
2. Both proteins have known UniProt accession identifiers.
3. The interaction is non-redundant in the network.
4. A protein pair has at least one solved or homologous structures in the same PDB file
(biological unit). To determine the interaction interface region, only the structure of
a interaction protein pair with highest sequence identity and coverage was selected.
3.4.2 Interface Identification
For each interaction protein pair, interface residues were defined by analysing the PDB
binary complexes using the POPSCOMP [102] tool, which calculates residue solvent ac-
cessibility and identifies the exposed surface area of molecules. Protein binding interface
residues were determined by subtracting the solvent accessible surface area (SASA) of the
protein complex from that of the two isolated proteins:
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∆SASA(A : B)interface = SASAA + SASAB − SASAA:B (3.1)
where SASA(A:B)interface are the residues located at the binding interfaces of protein A
and B complex.
An interaction protein pair is selected for 3D PPIN construction if the interface region of
the protein complex is identified. Structured and unstructured regions were identified for
each protein in the human 3D PPIN (Figure 3.1). The former includes surface, interface
and core regions, while the unstructured regions refer to disordered region that are outsides
of Pfam domain boundaries and are predicted as disordered by DISOPRED [176]. Details
of determination of surface, interface, core and disordered regions are given in Chapter 4.
3.4.3 Data Collection and Analysis of SNPs
Human gene variation datasets were downloaded from databases, including dbSNP (build
135) [123], OMIM (November 2013 downloaded) [124] and COSMIC (v66 250713 release)
[125]. Only single point missense mutations, which change amino acids on protein se-
quences, were selected for this study. The initial number of nsSNPs in each dataset is
listed in Table 3.6 Section a. The dataset from dbSNP was used as the control dataset
and is referred to as common nsSNPs (nsSNPsC), while the datasets obtained from OMIM
and COSMIC databases represent germ-line disease nsSNPs and somatic cancer nsSNPs,
respectively.
This study uses the UniProt accession identifier database as a protein reference. The
initial dbSNP dataset contains 800,332 missense mutations referenced with RefSeq protein
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dbSNP (nsSNPsC) OMIM (nsSNPsGD) COSMIC (nsSNPsSC)
a. Initial numbers collected from databases :
nsSNPs 800,332 24,932 1,023,837
b. After mapping to UniProt sequences:
nsSNPs 759,431 19,002 912,816
c. After filtering data with criteria (as described in the text):
nsSNPs 480,762 12,761 202,719
proteins 17,744 2,031 17,741
d. After mapping on human 3D PPIN :
nsSNPs 165,288 6,698 76,924
proteins 8,029 1,115 7,746
Table 3.6: Numbers of nsSNPs collected from databases. The number of nsSNPs
in each dataset in four stages of filtering procedure is listed. The details in filtering nsSNP
datasets are given in ”3.4.3 Data Collection and Analysis of SNPs”.
identifiers. NCBI protein database assigns each isoform of a protein with an unique RefSeq
identifier, while UniProt assigns each protein with one accession identifier. This could
lead to duplicate counts in SNP numbers and mismatch nsSNP positions when mapping
from RefSeq to UniProt. In some cases, sequences of the same protein in NCBI and
UniProt differ slightly. A nsSNP in the control dataset, which was found at a inconsistently
documented residue position, was retained in the dataset. After mapping protein identifiers
from RefSeq to UniProt and filtering out mismatched protein residues due to different
protein isoforms, the dataset contains 759,431 nsSNPs. The dataset was further filtered
with the following criteria:
• nsSNPC records do not exist in either nsSNPGD or nsSNPSC dataset.
• Only the nsSNPsC which occur in the proteins of human PPIN are selected.
The resulting control dataset (nsSNPsC) contains 480,762 nsSNPs in 17,744 proteins.
Germ-line disease nsSNPs which mapped on the residues that differed between the two
databases were filtered out from nsSNPGD dataset. An example is given in Figure 3.20.
The sequence of ADRB1 (UniProt accession Identifier P08588 RefSeq identifier NP 000675)
is documented differently at residue position 389, with an Arginine in UniProt database
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and a Glycine in NCBI dataset. This residue has been reported to be related to cardio-
vascular disease (p.R389G; rs1801253) [209]. Therefore, the checking of residue indexes
and amino acids between the sequences of RefSeq and UniProt is required. A total of
71 nsSNPsGD were found at inconsistently documented residue positions. Having filtered
out those nsSNPs and the nsSNPs that mapped on mismatched isoform sequences, 19,002
nsSNPs remained in the nsSNPGD dataset. The dataset was then further filtered. Only
the nsSNPsGD which occur in the proteins of human PPIN were selected. At this stage,
nsSNPGD dataset contained 12,761 nsSNPs in 2,031 proteins.
The third nsSNP dataset contains somatic cancer missense variants obtained from the
COSMIC database, which documents somatic cancer mutations and related information
curated from the primary literature. The initial number of mutations collected from the
database is 1,524,611 cancer mutations, among which 1,023,837 are missense variants. The
nsSNPs are referenced with gene names and HGNC idnetifiers (HUGO Gene Nomenclature
Committee) [210]. Having mapped gene names with UniProt identifiers, 912,816 nsSNPs
remained in the nsSNPSC dataset. The dataset was further filtered with the following
criteria:
• A nsSNP is selected if it is annotated as ”Substitution - Missense” and ”Confirmed
somatic variant”.
• Only the nsSNPsSC which occur in the proteins of human PPIN are selected.
The resulting somatic cancer mutation dataset (nsSNPsSC) contains 202,719 nsSNPs in
17,741 proteins.
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Figure 3.20: An example of differently documented protein sequences between
NCBI and UniProt databases. The residue at position 389 in ADRB1 is documented
with different amino acids in the NCBI and UniProt databases.
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The selected nsSNPs in each dataset were mapped onto protein complexes in the human
3D PPIN. The number of nsSNPs mapped on the 3D PPIN is given in Table 3.6d. Those
nsSNPs were further classified by the regions where they were occurring, which are surface,
interface, core and disordered regions. The number of nsSNPs in each region is listed in
Table 3.1.
The hypothesis is that the larger the region, the higher number of mutations can be found
at this site. In order to compare the propensity of nsSNPs amongst regions of occurrence,
including nsSNPssurface, nsSNPsinterface, nsSNPscore and nsSNPsdisordered, without bias
due to their intrinsically different size, the number of classified nsSNPs by region was
normalised by the corresponding size of the region. The following formula was used to





To avoid the possibility that the observed propensities were biased by a few proteins with
large number of nsSNPs, confidence intervals (CI) at 95% were calculated by bootstrap
re-sampling with 10,000 replicates. The statistical significance of differences between the
propensities was estimated with pair-wise Wilcoxon comparison tests. These re-sampling
and statistical analyses were performed with R [211]. These statistical analyses were also
used for the nsSNP enrichment assessment under different criteria described in the follow-
ing sections. Detailed statistical analyses are given in section ”3.4.4 Statistical Evaluation”.
The interface disease-related nsSNPs were further classified into inter-interface specific
(nsSNPsS Inter), intra-interface specific (nsSNPsS Intra) and others (nsSNPsMulti). An in-
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Inter-interface (nsSNPS Inter) Intra-interface (nsSNPS Intra)
nsSNPGD 256 500
nsSNPSC 2,411 1,888
Table 3.7: Numbers of co-localised interface nsSNPs.
house written script was used to identify SNPs classes nsSNPS Inter and nsSNPS Intra. A
SNP is recognised as nsSNPS Inter by the script if at least one other interface nsSNP is
located on the shared interface of the interaction protein pair considered and is involved in
the same disease. On the other hand, a SNP is recognised as nsSNPsS Intra if at least one
other interface nsSNP is co-localised at the same interface of a protein in the considered
complex and is involved in the same type of disease. The number of nsSNPs in class
nsSNPS Inter and nsSNPS Intra is listed in Table 3.7.
3.4.4 Statistical Evaluation
In this study, we are interested in characterising the features of disease-related mutations,
particularly in identifying the tendency of mutations to occur at specific protein regions.
The enrichment of mutations at each protein region was estimated by calculating the
propensity of mutation-occurring residues at the protein region (surface, interface, core
or disordered). A propensity which is larger than 1 (0 after logarithms) indicates that
mutations occur frequently in a studied region. The propensities were also used to compare
the relative enrichment of mutations between different protein regions. The statistical
analyses were performed using R [211]. The details of the statistical analysis used in this
study are described as follows.
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Enrichment of Mutations
Assuming that mutations occur at random over protein sequences, we would expect to find
a greater number of mutations at a larger protein region (the region containing the higher
number of residues) than at a smaller protein region by chance. For instance, we expect
to find more mutations at protein surfaces than at interfaces. Therefore, to compare the
mutation enrichment between protein regions, the mutation numbers are normalised by
the size (number of residues) of the region. This was calculated using the formula (Formula
3.2) given in the previous section ”Data Collection and Analysis of SNPs” to obtain the
propensities of the mutations in different protein regions.
Re-sampling
In order to estimate the observational bias induced by intensively studied proteins, the
bootstrapping method was used to randomly re-sample from the pool of human proteins
that have structural and mutation information. 10,000 replicates were generated for each
pre-defined protein region with a mutation dataset (nsSNPsC , nsSNPsGD or nsSNPsSC).
95 percentage confidence intervals were calculated from bootstrapping distributions. The
density plots were generated to show the distributions of re-sampled datasets from the
bootstrapping method. The boot function from the R programming language was used
to perform the data re-sampling.
Statistical Significance
Statistical differences between propensities were estimated using the Wilcoxon Mann-
Whitney test. This is a non-parametric test and assesses whether two populations have
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an identical distribution. The wilcox.test() function from the R programming language
was used to perform null hypothesis test.
Enrichment Compared with the Control
The enrichment of disease-related mutations in comparison with the control mutation
dataset at each protein region was estimated using the fold-change, which is determined
by:
Fold Change = x¯ / y¯ (3.3)
where (1) y1, y2, ..., yn is the control; and (2) x¯ and y¯ are the means of the propensities
obtained from the two compared mutation datasets at a specific protein region.
3.4.5 Definition of SNPs Disease Category
A previous study by Goh et al. [10] classified the diseases from OMIM genetic variation
records into 21 disease types (Appendix A). This is currently the only available annotation
for categorising OMIM variants. In this study, each nsSNPGD was assigned with a disease
type according to this classification.
For the cancer nsSNP dataset, the cancer category of nsSNPsSC was defined by the cancer
primary type. The cancer types with less than 10 nsSNPs in the COSMIC dataset were
filtered out, this resulted in a final list with a total of 27 cancer types (Appendix B).
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3.4.6 nsSNPs at Secondary Structure Elements
The composition of secondary structure of a protein was defined using DSSP [200]. By
giving a PDB structure file of a protein, DSSP assigns the most likely class of secondary
structure to each residue of the protein with a character indicating the secondary structure
that the residue is part of. For proteins that do not have resolved structures, homologous
structures (from the PSI-BLAST results described in the previous section) were used for
this analysis.
Based on secondary structure profiles, DSSP secondary structure assignments were grouped
into two main classes defined by us as stiff and flexible regions. Stiff regions include helix
(H, G, I) and strand (B, E) structures in the secondary structure profile, while flexible
regions include loops and turns (T, S, L). The three classes of nsSNPs, surface, interface
and core nsSNPs, were assigned with propensities at protein stiff and flexible secondary







The propensity of nsSNPs at these two SS groups (stiff/flexible) was calculated for each
nsSNP class and their pairwise comparison was performed using the previously described
statistical assessment.
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3.4.7 Functional Site nsSNPs
The functional specificity of disease-related SNPs was examined with a structure-based
measurement by screening the nsSNPs that are at or close to protein functional sites or
post-translational modification (PTM) sites.
To investigate the enrichment level of close-to-functional-site nsSNPs, the functional site
annotation was first downloaded from UniProt. It includes active sites, metal binding sites,
binding sites, cleavage sites, inhibitory sites, and breakpoint sites. 2,100 proteins in the
3D PPIN were annotated with functional site information. An in-house script was written
to screen protein structure coordinates and detect residues that are close to functional
sites in 3D space. The distance between a functional site residue and any other residue
was calculated by measuring the distance between Cα atoms from the two residues. A
threshold value of 8 A˚ was used to identify residues close to the functional site. The
nsSNPs, whose positions overlapped with these selected close-to-functional-site residues
were defined as close-to-functional-site nsSNPs and were analysed using the formula 3.5
and the statistical assessment.




The same analyses were performed for PTM sites. The PTM site annotation for human
proteins was obtained from UniProt and PTMcode [204] databases. 4,370 proteins in the
3D PPIN were annotated with PTM site information. The same distance threshold and
procedure were used to identify nsSNPs that are at or close to PTM sites in 3D space and
calculate the enrichment of nsSNPs that are at or close to PTM sites.
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3.4.8 Amino Acid Change of nsSNPs
In order to measure the frequency of different types of amino acid changes induced by
nsSNPs, the amino acids were classified as non-polar (G, A, I, L, M, F, W, V), polar
(S, T, N, Q, C, Y), positively charged (R, H, K), and negatively charged (D, E) residues
according to their physico-chemical properties. Proline (P) was not assigned to any of
these four physico-chemical classes since any residue change to or from proline is con-
sidered as a drastic change, so changes including proline were defined as an independent
class. Figure 3.6 shows all the possible changes between residue classes. Apart from the
aforementioned amino acid changes involving proline, drastic amino acid changes include
substitutions between non-polar and positively charged residues, non-polar and negatively
charged residues, and between positively changed and negatively charged residues. The
rest of amino acid changes are defined as moderate changes. The changes between amino
acids from the same class were defined as moderate but not included in our analysis.
The frequency of amino acid change types was calculated relative to drastic and moderate
changes. For example, the frequency of changes between non-polar and polar residues was
calculated as follow:
Numbermoderate change sub grp/Numbermoderate change
3.4.9 Analysis of Functional Similarity of Interaction Protein Pairs
To measure the functional similarity between an interaction protein pair, the method TAS
[212] was implemented to measure the GO term specificity for the two proteins. Human
protein GO annotations were downloaded from UniProt-GOA [213]. Proteins in the 3D
PPIN were annotated with Biological Process (BP) functional terms. The GO database
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termdb was also downloaded from the Gene Ontology web server (date 31 August 2013)
to build a GO functional tree of the 3D PPIN. TAS combines the notions of topological
distance and the lowest common ancestor distance methods (original paper Yu et al. [212]).
The Lowest Common Ancestor Node (LCAN) is the lowest level of GO term that a pair
of interaction proteins shares in common. All the parents nodes of this LCAN are the
common ancestor nodes of this interaction protein pair. In other words, each node in the
tree is not only the lowest common GO term of the protein interaction pairs considered,
but also the common GO term of all the interaction pair of all its children nodes (Figure
3.21). Therefore, the fewer number of interaction protein pairs the LCAN of a considered
protein pair contains, the higher specificity the LCAN is for the protein pair. On the other
hand, the protein pairs were annotated as not being functionally similar if their LCAN
is the GO root node (node 0 in Figure 3.21). A probability measure of the functional
similarity given by a LCAN was calculated as following:
P = n/N
where n is the number of protein pairs in the common ancestor node, and N is the total
number of protein pairs in the GO functional tree of the human 3D PPIN.
To study the consequences of nsSNPs on protein functions, the functional similarities
between interaction protein pairs were used to determine the association between the
types of diseases the nsSNPs lead to and the functions of the affected proteins. The PPIs
were classified as the ones in which both proteins are related to the same type of disease
(PPIsdisease), the ones whose partners are not involved in the same disease (PPIsdiff ), and
the ones that are not related to any disease (PPIsnon). A protein pair, in which only one
of them was disease-related, was classified as PPIsnon. The functional similarity according
to this scheme was calculated for proteins that are related to germ-line diseases and to
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cancer and compared over the three classes of PPIs.
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Figure 3.21: Total ancestry similarity measure. Nodes in the tree contain proteins
which have the function of the node. Protein A, for example, has the function of the
nodes ”01.01.01” and ”02.02”. Nodes are also assigned with PPIs, when the node is the
common functional ancestor of the protein pair. PPI A:B, for example, indicates the
common functional ancestor nodes of Protein A and B. TAS(A:B) indicates the TAS score
of protein A and B.
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3.4.10 Function Annotation of SCOP Domain Superfamilies
Protein domains in the human 3D PPIN dataset were assigned with domain function cate-
gories using functional annotation of SCOP superfamilies [214, 215]. The domain function
annotation (scop.annotation.1.73.txt and scop.larger.categories) was downloaded from the
SCOP website. The nsSNPsGD were mapped onto the function categories relative to the
affected domains. The frequencies of nsSNPsGD in each function category are shown in
Figure 3.22.
Figure 3.22: The functions of nsSNPsGD occurring domain.
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3.4.11 Prediction of nsSNP Impact
PolyPhen2 and Provean-1.1 [147] were installed on the local Unix machine to perform pre-
dictions in batch on nsSNP impact. The nsSNPGD and nsSNPSC datasets were analysed
and compared between classes, including surface, interface, core and disordered.
3.4.12 Classification of Interface nsSNPs
Interface co-localised nsSNPs are classified into three classes: inter-interface specific
(nsSNPsS Inter), intra-interface specific (nsSNPsS Intra) and others (nsSNPsMulti). The
implementation of interface nsSNP classification is presented as the following pseudo code.
Declare an array SNP arr store interface nsSNPs
Set n to be number of interface nsSNPs to be screened
FOR counter1 = 0 to n-1 :
FOR counter2 = 0 to n-1 :
IF SNP arr[counter1] is not SNP arr[counter2]
AND SNP arr[counter1] and SNP arr[counter2] at interfaces of a protein pair
AND SNP arr[counter1] and SNP arr[counter2] relate to the same disease:
IF SNP arr[counter2] on the opposing interface of SNP arr[counter1]
AND SNP arr[counter1] not yet being reported as a nsSNPInter:
report SNP arr[counter1] as a nsSNPInter
END IF
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IF SNP arr[counter2] on the same interface of SNP arr[counter1]
AND SNP arr[counter1] not yet being reported as a nsSNPIntra:
report SNP arr[counter1] as a nsSNPIntra
END IF
ELSE:





Pipeline to Generate 3D
Protein-Protein Interaction
Networks
Protein-Protein Interaction Networks (PPINs) have been largely used in the biological
sciences to represent the gene/protein associations and the physical interactions occurring
in the cell. By adding functional information to proteins within PPINs, the analysis
can highlight hidden properties and assign more reliability to their association and the
implied cellular processes. A detailed introduction of the PPIN applications and uses in
biology has been presented in the first chapter. Recent studies have integrated structural
information within PPIN in order to investigate the biological system at the molecular
level and explore the underlying mechanisms at the atomic and molecular detail. In this
chapter, the development of a pipeline for mapping 3D data to PPINs will be presented,
as well as the comparison with the currently available 3D PPIN analyses.
89
Chapter 4. Pipeline to Generate 3D Protein-Protein Interaction Networks 90
4.1 Introduction
Over the last few years, analyses of 3D PPINs have gained momentum for their importance
in studies such as understanding protein binding mechanisms, molecular properties of
hub proteins, protein-protein interaction predictions, identifying druggable protein-protein
interactions, and the impact of human genetic mutations on protein complexes. Several
research groups have used 3D PPINs to conduct systematic studies on human disease-
related mutations and revealed the molecular properties of those mutations [26, 27, 28,
91].
However, those studies have been limited by the relatively low availability of protein 3D
structures. Homologous structures and structure modelling methods have been used to
expand the 3D space of PPINs. Using a different approach, homologous proteins were
used as structural proxies for the mapping of genetic variants and subsequent inference of
complex interactions. In this chapter the automated pipeline for constructing 3D PPINs
is presented, starting from the PPI data collection, searching for protein structures, the
detection of interaction binding regions and the mapping of human mutation data onto
these.
4.2 Materials and Methods
The automated pipeline of human 3D PPINs is constructed following a sequential process
(Figure 4.1). Each protein in a 3D PPIN is annotated not only by its interaction rela-
tionship with other protein but also by the structural, functional and genetic information
selected.
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Figure 4.1: The automated pipeline for 3D protein-protein interaction network
constructions. The processes coloured in light blue contain protein structure information.
Chapter 4. Pipeline to Generate 3D Protein-Protein Interaction Networks 92
Database (version) Identifier Num. of PPIs
BioGRID-ORGANISM-3.2.101 UniProt 209,838
DIP 20130131 UniProt/RefSeq 4,315
HPRD Release9 062910 RefSeq, Gene symbol 39,240
IntAct (downloaded on 05 June 13) UniProt 95,813
MINT 2012 02 06 entrez 33,954
STRING 9.05 Ensembl 4,445,596
Table 4.1: Datasets obtained from PPI databases. The number of human PPIs,
the downloaded version/date, and the protein identifiers used in the databases.
4.2.1 Integration of Human Protein-Protein Interaction Datasets
Human PPI datasets were obtained from six publicly available databases, including Bi-
oGRID [60], DIP [61], HPRD [59], IntAct [62], MINT [63] and STRING [64]. The dataset
from Havugimana et al. [67], which contains novel PPIs derived from AP-MS experiments,
was also obtained. Only the protein interactions in which both are human proteins were
selected. The initial number of PPIs from each database is reported in Table 4.1.
To integrate the PPI datasets, the pipeline only selects the protein interactions for which
both proteins have an UniProt [203] reviewed accession identifier. The mapping between
UniProt accession identifiers and other protein references are based on the identifier map-
ping provided by UniProt, which was downloaded from the UniProt FTP repository
(ftp.uniprot.org). At this stage, the PPI dataset was not filtered with stringent crite-
ria. However, the STRING database includes not only experimentally determined protein
interactions, but also putative interactions obtained from functional association analysis
such as genome context and co-expression analysis. In the downloaded STRING dataset
(v9.05), only 6 % of PPIs/protein associations (263,666 out of 4,445,596) have experi-
mental evidence of physical interactions. The putative PPIs can only indicate that both
proteins of a PPI are a part of a biological pathway or have functions in common, but do
not indicate direct physical interactions between associated protein pairs. The automated
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Total collected PPIs Predicted PPIs
Integrated from databases 1,878,098 1,689,416
Human 3D PPIN 39,387 25,773
resolved homologous resolved homologous
4,423 34,964 657 25,117
Table 4.2: Number of PPIs obtained from STRING database. The numbers
of initially collected PPIs and the PPIs in the 3D PPIN are given in the column ”Total
collected PPIs”. These numbers includes the predicted PPIs obtained from STRING
database. The column ”Predicted PPIs” gives the numbers of PPIs obtained from STRING
predicted PPI dataset and the PPIs in the 3D PPIN. The last row of the table gives the
numbers of the PPIs which either have resolved structures or were assigned with homology
models.
pipeline assigns structure complexes to PPIs that gives solid evidence of the physical in-
teractions and reduce the false positive rate. The datasets which were integrated with the
STRING dataset and without the STRING dataset both showed enrichment of disease-
related mutations (nsSNPsGD and nsSNPsSC) at protein interface regions. A summary of
the increases to the human PPIN by integrating STRING dataset is given in Table 4.2. By
including the STRING predicted PPIs, the total PPIs increased to 1,878,098 interactions
in the human PPIN.
4.2.2 Defining Protein Domains
The Protein Data Bank (PDB) [79] stores roughly around 5,000 human proteins in com-
plexes. These are only about a quarter of estimated human proteins and many of them
containing only partial protein structures. In order to construct the human 3D PPIN con-
taining the largest number of protein structures, proteins are assigned with their domains
boundaries.
A protein domain is a subunit of a protein structure which can fold independently and ex-
ist stably in isolation. Throughout evolution, functional domains shuﬄed and recombined
to produce new proteins. Thus, the same domains can be found in different proteins, espe-
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cially in eukaryotic organisms [83]. Finding homologous domain structures is an effective
alternative for the 3D network construction.
Current available databases of protein domains include 3did [216], CATH [217], SCOP
[218] and Pfam [219]. In this study, the Pfam domain sequence library was used to define
protein domains for the following two reasons: Firstly, Pfam provides the profile Hidden
Markov Models (HMMs) for the domain family, which are probabilistic models of seed
alignments that enables fast and accurate sequence similarity searches using the HMM
software HMMER3 [220]. Secondly, the output results from HMMER contain an e-value,
which is the number of non-homologous hits in a specific database. The e-value allows
users to filter the domain assignment with a given threshold.
The Pfam library and HMMER3 are embedded in the automated pipeline as follows:
1. Pfam 26.0 domain sequence library (Pfam-A.hmm), which was downloaded from
Pfam FTP repository (http:// pfam.sanger.ac.uk/).
2. The sequence similarity-searching tool HMMER3 (http://hmmer.janelia.org/) was
downloaded and installed on the local Linux machine.
3. Human protein sequences in FASTA format were downloaded from the UniProt FTP
repository.
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Figure 4.2: Protein domain assignment. Examples of defined domains and the
file data format. (A) Output result from HMMER. (B) The pipeline generated results
extracted from the HMMER output file.
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HMMER hmmsearch assigns domain definitions to query sequences of the human PPIN.
The pipeline extracts the output from HMMER (Figure 4.2A) and generates a results file
with format shown in Figure 4.2B. The results are then filtered with the following criteria:
(a) The e-value of an assigned domain is smaller than 1e-3. (b) When two assigned domains
of a protein overlap in the same region (sequence-based), the one with the lower e-value
is selected. The total number of 16,471 proteins in the human PPIN were assigned with
4,706 different domains.
4.2.3 Sequence Alignment and Homologous Structure Detection
The identification of both experimental structure complexes and homologous complexes
of PPIs is based on the output of the sequence alignment tool PSI-BLAST. The detailed
implementation is described in this section.
The sequence alignment tools PSI-BLAST and T-Coffee were embedded in the automated
pipeline as follows:
1. The local sequence alignment tool ncbi-blast-2.2.26+ [221] was downloaded from
NCBI FTP repository (ftp.ncbi.nlm.nih.gov) and installed on the local Linux ma-
chine.
2. PDB biounit entries were downloaded from RCSB PDB FTP repository (ftp.wwpdb.
org/pub/pdb/data/biounit/). The sequences of PDB structures were extracted
and pre-formatted into a blast sequence library using the ncbi-blast-2.2.26+ make-
blastdb command.
3. The profiles of PDB structure sequences were generated to record residue index
information (Figure 4.3E).
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4. The multiple sequence alignment tool T-Coffee [222] was downloaded and installed
on the local Linux machine (T-COFFEE distribution Version 9.02.r1228.tar).
To identify resolved and homologous structures of proteins in the human PPIN, the BLAST
command psiblast searches human protein sequences against the pre-compiled PDB se-
quence library with threshold e-value e-3 and 3 iterations. The pipeline extracts the
information of hits and the sequence alignments from blast results (Figure 4.3A), and gen-
erates an output file Human.blastAlignPdbStrucutre containing all the blast results
(one example shown in Figure 4.3B).
To optimise the sequence alignments between human proteins and PDB structure se-
quences, T-Coffee is implemented to re-align the sequence hits from PSI-BLAST (Figure
4.3C). Based on the domain assignments from HMMER, the pipeline extracts the align-
ments for the selected domain regions (Figure 4.3D). The following rules are applied to
select the structures that cover the domain regions:
• The detected structure of a protein domain covers more than 80% of the protein
domain sequence.
• The sequence identities of domain region alignments are calculated as the number
of identical amino acids between two sequences divided by the length of the domain.
The pipeline selects domain structures which have sequence identity higher than
30%.
The selected domain sequential and structural information are recorded in the file Hu-
man.domStructure and are used to construct 3D PPINs, which is described in the next
section.
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Figure 4.3: Protein local sequence search. Example of PDB structure searching
results and the file format. (A) Output result from NCBI PSI-BLAST. (B) The pipeline
generated results extracted from PSI-BLAST output file. (C) The sequence alignment be-
tween a protein sequence and PDB sequence from T-Coffee. The coloured regions indicate
domains listed in (D). (E) PDB structure sequence profile.
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Figure 4.4: Molecular solvent accessible surface area.
4.2.4 3D Interaction Network Construction
Having identified protein domain structures, the pipeline constructs the human 3D PPIN.
Firstly, the pipeline selects PPIs whose protein pairs are contained in the same PDB entry.
When more than two PDB entries are found for a interaction protein pair, the PDB entry
with the highest sequence identity to the protein pair, is selected. The total of 9,091
proteins in the human PPIN were found to have either resolved or homologous structures
in the same PDB entries with their interaction protein partners.
To determine the physical interactions of protein pairs, which have domain structures
in the same PDB entry, the tool POPSCOMP [102] was used to generate the profiles
of normalised Solvent Accessible Surface Area (SASA) (Figure 4.4) and the buried area
upon complex formation of protein pairs. A surface residue is considered to be part of a
protein interface region if it buries more than 15% of its SASA upon complex formation.
To ensure the physical interaction of proteins pairs, the pipeline selects the PPIs if at least
2 interface residues from each protein of a interaction pair are identified.
The interaction protein pairs for which homologous structures were used for the identifica-
tions of binding regions were mapped with the relative position using sequence alignments.
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Figure 4.5: Mapping the relative position of protein interface region. (A)
The homologous structures of protein HLA-C and KIR3DL3. The regions shown in solid
colour with sphere representation indicate the binding regions of the two proteins. (B) The
sequence alignment between the homologous (PDB 3vh8 chain A) and protein HLA-C. The
pipeline generates the file recording sequence alignments of proteins and their homologous
structures, and related information. The first line states the domain information of the
protein and the value of the sequence identity (highlighted in red). >ptn: indicates the
protein sequence. >pdb: indicates the structure sequence. >ire: indicates the residues
that were identified to be at interface region of the structure. The putative interface
residues are highlighted in colour orange.
An example shown in Figure 4.5, an homologous structure (PDB entry 3vh8) of protein
HLA-C domain MHC I was used to calculate the SASA values of residues and to identify
the residues that have the physical contact with the partner protein KIR3DL3. In Figure
4.5, the region shown in solid green sphere representation indicates the binding region of
the homologous structure of HLA-C. The relative binding region of HLA-C was identified
through the sequence alignment.
The resulting 3D PPIN contained 8,249 proteins with 39,387 interactions. Each pro-
tein was annotated with structure regions, including surface, interface and core using the
method described in this section.
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4.2.5 Inter-domain Disordered Region Prediction
The importance of protein disordered regions in mediating protein interactions and func-
tions were described in chapter 2. In this project, the disordered region is defined as
structural elements outside of domains and predicted to have a functional role by the
predictor DISOPRED [176]. These flexible structural regions are distinctive to loop sec-
ondary structures. The predictor DISOPRED is embedded into the pipeline to predict
the disordered regions of proteins in the 3D PPIN. The implementation is described in the
following:
1. blast-2.2.26 was downloaded and installed on the local Linux machine.
2. BLAST non-redundant sequence database was downloaded (ftp://ftp.ncbi.nlm.nih.
gov/blast/db/nr.*.tar.gz).
3. The sequence profiles of the proteins in the human 3D PPIN are generated using
PSI-BLAST to search against the non-redundant sequence database.
The protein sequence profiles of proteins generated from PSI-BLAST are used by the
pipeline to generate a symmetric vector of residues. DISOPRED [176] takes the residue
vector as input file for protein disordered regions prediction.
4.2.6 Protein Sequence Profile
The pipeline generates the sequence profile of proteins in the human 3D PPIN. The profile
documents different protein regions defined in the last two sections, including surface,
interface, core and disordered regions. One example shown in Figure 4.6.
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4.2.7 Mapping of SNP Data
As described in chapter 3, three human genetic variant datasets were obtained from
databases including, dbSNP, OMIM and COSMIC. They are representing different types of
genetic variation: general variants, germ-line disease-related variants, and somatic cancer
variants respectively. The occurring positions of SNPs are also annotated in the sequence
profile as shown in Figure 4.7.
Each group of nsSNPs are classified by the occurrences of the protein regions. The sequence
profile is used to divide the nsSNPs. A nsSNP is classified as a surface nsSNP if the relative
position of sre: sequence is annotated as S and the relative position of ire: sequence is
annotated as -. Whereas, a nsSNP is classified as an interface nsSNP if the relative
position of ire: sequence is annotated as I. The remaining residues at domain regions
with annotations of D symbol on dom: sequence, and annotations of - symbol on both
sre: and ire: sequences are defined as core region residues. The nsSNPs occurring at
those residues are classified as core nsSNPs.
Moreover, the residues annotated with a * symbol on dis: sequence and - symbol on dom:
sequence are defined as disordered region residues. The occurrences of nsSNPs at those
residues are classified as disordered region nsSNPs.
The total number of nsSNPs in each class and a detailed analysis were presented in the
previous chapter.
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4.2.8 Comparison with Other Existing Applications
Two recent studies [27, 24] presented human 3D network development and the implication
of the networks. In this section, a summary of the comparison with those two studies is
presented in Table 4.3.
Our approach is substantially different in:
1. Being able to start from PPIN and automatically extract the Common Variants,
and disease-related nsSNPs onto different regions: Surface, Core, Interface and inter-
domain Disordered region. To our knowledge, no existing method is offering this.
2. We extract the SNP occurrences and propensities by mapping onto human 3D struc-
tures and corresponding positions on relative homologous structures. This allows us
to expand the existing sequence-3D gap and enrich our data (total number of 3D
PPIN)
3. We extract nsSNPs co-localised on the same and opposing interfaces.
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Protein struc-
tures
resolved structures of the
two proteins in complex,
or homologous mapping
through iPfam
1) entirely or partially re-
solved protein structures;
2) homologous models
from Modbase; 3) ho-
mologous structures; 4)
domain-domain struc-
tural templates in 3did
database. (The homolo-
gous structures and tem-
plates were used as tem-
plates to model the struc-
tures)







faces given in 3did or iP-
fam databases
1) covalent interactions,
defined as two sulfur
atoms of a pair of cys-
teines at a distance ≤ 2.56
A˚; 2) hydrogen bonds, de-
fined as all atom pairs N-
O and O-N at a distance
≤ 3.5 A˚; 3) salt bridges,
defined as all atom pairs
N-O and O-N at a dis-
tance ≤ 5.5 A˚; 4) van der
Waals interactions, de-
fined as all pairs of carbon
atoms at a distance ≤ 5.0
A˚.
POPSCOMP method
was used to calculate the
SASA and identify the

















1) enrichment of muta-
tions and SNPs on inter-
action interfaces (compar-
ing the observed number
of mutations and SNPs
on interfaces to the rel-
ative length of the pro-





1) enrichment of nsSNPs
(missense variants) at pre-
defined protein regions;
2) functional roles of nsS-
NPs; 3) pair-wise interface
nsSNPs calculations.
Table 4.3: Comparison between 3D PPINs.
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4.2.9 Applications
The applications of the automated pipeline will be presented in this section. Human
PPI sub-networks were generated for the studies focused on different proteins, including
B-RAF, hub proteins and LAMIN.
The B-RAF Mutants
The application summarised here is published in the paper of Satoh et al. [33], where more
details about the studied system are given. Here I report my contribution to the work.
The mutations p.V600E, p.600DLAT and p.T599A (Figure 4.8) were found in Langerhans
Cell Histiocytosis (LCH) patients. The automated pipeline developed in this thesis was
used to search for domain definition and identify the homologous structures of human
B-RAF. The protein was assigned with the domain RBD and Pkinase Tyr by searching
the Pfam-A domain library. The Pkinase Tyr domain was further investigated as it is the
domain in which those three mutants of our interests occur and was found with homologous
structures. The PDB structure (1WUH) with the highest sequence identity to the human
B-RAF protein sequence was used as the template to build the structure models of B-RAF
mutants using the tool Modeller 9v8 [223].
Our results showed that the 600DLATB-RAF insertion have the same structural and func-
tional effects as the V 600EB-RAF mutant on B-RAF that destabilise the inactive confor-
mation of the B-RAF kinase and consequently increase ERK activation. Whereas, the
T599AB-RAF mutant was found to be a germ-line polymorphism and not having effect on
the inactive conformation of the B-RAF kinase. Instead, T599A occurring at a major
phosphorylation site of the B-RAF activation domain suppress B-RAF activity.
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Figure 4.8: B-RAF kinase domain mutants. (A) Protein sequence alignments be-
tween reference (wild-type) sequence and patients’ sequences. The second column indicates
the patients’ ID number. (B-D) Comparison between wtB-RAF ((B), purple), V 600EB-RAF
structure ((C), cyan) and the modelled mutant 600DLATB-RAF ((D), grey). (B) Val600
(yellow) forms a hydrophobic contact with Phe468 (red arrow). In (C) and (D) charged
residues Asp and Glu (in orange) disrupt the hydrophobic network of interactions, stabil-
ising the active conformation of the P-loop. (D) Insertion Asp-Leu-Ala-Thr shifted Val600
and disrupt the hydrophobic cluster. (E, F) Comparison between models of WTB-RAF
((E), violet) and T599AB-RAF ((F), gold). T599AB-RAF substitutes a polar uncharged
residue with a hydrophobic residue, causing the loss of short-ranged interactions with
residues D576 and D594. Figure adapted from Satoh et al. (2012) [33].
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Promiscuous Residues of Hub Proteins
The application summarised here is published in the paper Fornili et al. [113], where more
details about the studied system are given. Here I report my contribution to the work.
Promiscuous residues at the binding interfaces of hub proteins play essential role in the
protein binding events. The flexibility of those residues enable the proteins to adopt
different conformation according to the partner proteins.
In the study of Fornili et al., two protein datasets were generated to study the properties
of promiscuous residues: SFull and SSoc. SFull is a non-redundant list of proteins generated
from PiSite database, while SSoc is composed of sociable proteins, defined as having at
least 3 structural partners and 3 different binding states. The interface residues of proteins
were defined with Binding Multiplicity (BM), which is the number of partner proteins
that a residue involves in the binding interfaces. The interface residues were classified into
three binding classes by BM value. Residues with BM > 2 were classified as cmulti, while
residues with BM = 1 were classified as cmono if belonging to monopartner proteins and
as cmono in multi if belonging to multi-partner proteins.
The pipeline was used to map human nsSNPs onto the relative positions on the studied
proteins in order to see whether promiscuous residues are prone to the mutations. Human
homologous proteins of SFull and SSoc proteins were identified using NCBI-BLAST. Human
nsSNP datasets were also obtained from dbSNP and OMIM, and defined as nsSNPsC and
nsSNPsGD, respectively. The position mapping between the studied proteins and human
homologous relied on the sequence alignments from the BLAST results. A total of 38 SFull
proteins and 25 SSoc proteins were annotated with nsSNP information.
Promiscuous positions in SFull proteins (orange) were found less rich with nsSNPsC than
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both classes of monopartner residues (cyan and blue). This observation was also found
in SSoc proteins with reduced statistic significance. This may suggest that the human
equivalent of the promiscuous positions considered here tend to be less tolerant to genetic
variation. The promiscuous residues are under higher level constraints in order to preserve
effective binding. The occurrences of mutations at promiscuous positions may be prone to
result in a lethal phenotype. On the other hand, the analysis of nsSNPsGD was strongly
affected by the small number of observations, which requires a larger human protein dataset
to obtain a more accurate investigation.
Figure 4.9: The occurrences of nsSNPs at promiscuous residues. Propensities of
nsSNPsC and nsSNPsGD in SFull and SSoc. (A) Propensities of nsSNPsC (light colours)
and nsSNPsGD (dark colours) relative to the interface residues of cmono (cyan), cmonoinmulti
(blue), cmulti (orange), cmonoinmulti(Soc) (green) and cmulti(Soc) (red). The propensity is
calculated per protein. The reported values are averages over SFull monopartner proteins
for cmono, S
Full multipartner proteins for cmonoinmulti and cmulti, and S
Soc proteins for
cmonoinmulti(Soc) and cmulti(Soc). (B) SNPs in the human survivin protein. SNPs found in
the interface region of survivin are labelled and represented as van der Waals spheres. A
survivin binding partner (borealin) is also represented as green cartoon (PDB ID: 2RAW).
Figure adapted from Fornili et al. (2013) [113].
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The Immunoglobin-like Domain of LAMIN
Mapping pathogenic mutations in Laminopathies onto the Lamin Ig-like fold. Laminopathies
are caused by mutations in A-type nuclear lamins. Although being quite accurately de-
scribed and mapped onto the LMNA gene, it is difficult to extract precise structural
information on the genotype-phenotype relation, due to the scarcity of resolved structures
for this gene.
Only the Ig-like fold domain has been structurally resolved, and therefore we used available
bioinformatics tools like PolyPhen-2, Fold X, Parameter OPtimised Surfaces, PocketPicker
and the pipeline developed in this thesis to characterise 56 missense mutations for position,
surface exposure, change in charge and effect on Ig-like fold stability. The striking result
was that the majority of mutations (21/27) associated with a skeletal muscle phenotype
mapped onto the Ig-like domain, are non-surface exposed and we predict them to affect the
stability of the Ig-like fold domain. Interestingly, the other 6 mutations clustered together,
showed increased surface exposure, and no effect on the protein stability.
We observed a clear separation (Figure 4.10A) of laminophaties specific phenotypic groups
Skeletal muscle, Lipodystrophy and Premature ageing and clustering on different regions
on the Surface/Core of the Ig-like fold. The relative positions matched different electro-
static surfaces, indicating a different possible impact of the mutations on the implicated
molecular mechanisms and nature of the interaction partners. The Skeletal muscle mu-
tations clustering in distinct, charged regions can affect lamin A/C -protein/DNA/RNA
interactions may suggest a distinct pathological mechanism for this phenotype.
The pipeline was used to extract nsSNP information of lamin. One missense SNP (p.T534S)
which is not known to be related to disease was found in the nsSNP dataset obtained from
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dbSNP and was used as a control. This nsSNP was found to be in a region of the Ig-like
fold domain but does not overlap with any of the clusters that contain pathogenic muta-
tions (Figure 4.10B). Moreover, it was predicted to have a low ∆∆G by Fold X, and to be
benign by PolyPhen2.
Figure 4.10: The occurrences of nsSNPs in LAMIN Ig-like fold domain. (A)
The six skeletal muscle cluster residues (green) and all residues associated with premature
ageing (purple) and lipodystrophy (orange) are highlighted in the surface representation,
and can all be seen to form separate clusters. (B) Figure adapted from Scharner et al.
(2013) [224].
Chapter 5
Summary and Future Direction
The usage of Protein-Protein Interaction Networks (PPINs) have progressed from merely
abstract to detailed representation of interacting protein pairs annotated with functional
and structural information. The structural information extracted from 3D PPINs enables
the study, for example, of biological mechanisms occurring in the cell at the molecular
detail, and can result very useful for the detection of druggable candidate PPIs for the
clinical treatment. Efforts have been made to identify the features of human disease-
related genetic variation using human 3D PPINs [26, 91, 27, 28]. It is commonly agreed
that protein interfaces play an important role for protein binding activity. An interesting
finding confirmed in this work is that mutations occurring at interface regions of protein
complexes are more likely to result in disease than mutations occurring at other protein
regions. This has confirmed previously observed enrichment of disease-related variants at
interface regions [27].
However, the number of experimentally resolved human protein structures is compara-
tively small considering the number of known human proteins. Homologous structures
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and structure modelling methods have been used to compensate the low number of ex-
perimentally determined structures and increase the 3D space of PPINs. In the study of
Mosca et al. [24], homologous structures were selected with stringent criteria to build pro-
tein complex models. The structure complexes of domain-domain interactions were used
to increase the size of human 3D PPIN [216]. This approach has significantly increased
the number of structure complexes mapped to PPIs, with more than 4,000 proteins in the
network compared to earlier work by Wang et al. [27] containing less than 3,000 proteins
in the 3D network.
In this study, we aimed to enlarge the 3D space of PPINs to annotate most proteins in
the network with functional, structural and genetic information. An automated pipeline
was developed for generating human 3D PPINs. This has the practical advantages, that
allows for a standardised procedure for 3D PPIN construction. It has been used here
for human 3D network constructions and can be used to construct 3D PPINs of other
organisms in the future. The flexibility of the pipeline also allows the implementation of
studies on specific diseases with data generated from next generation sequencing or GWAS
studies. Moreover, such a pipeline allows the user to assign the thresholds for homologous
structure selection and interface residue selection. With a sequence identity target of
more than 30% for homologous structure selection, the human 3D PPIN constructed for
this study contains more than 8,000 proteins. Finally, the pipeline has the function of
mapping available datasets of human genetic variation onto proteins constituting the 3D
PPINs. The human 3D PPIN generated for this study was further mapped with non-
synonymous Single Nucleotide Polymorphisms (nsSNPs) data obtained from databases
including dbSNP, OMIM and COSMIC. The nsSNP dataset from dbSNP was used as
the control dataset to be compared with disease nsSNPs from OMIM and COSMIC in
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order to differentiate the properties between disease and non-disease related nsSNPs. This
control dataset is noted as nsSNPsC , and was filtered by omitting the nsSNPs from OMIM
and COSMIC databases. The nsSNP datasets from OMIM and COSMIC represented
the Germ-line Disease nsSNPs (nsSNPsGD) and Somatic Cancer nsSNPs (nsSNPsSC),
respectively, and were analysed as two data groups.
The nsSNPs were classified and analysed by their occurrence in the defined protein re-
gions, including surface, interface, core and inter-domain disordered regions. Our analyses
showed an enrichment of nsSNPsGD at the protein interface regions as the aforementioned
study reported [27]. nsSNPsSC were also found to be enriched at the interfaces (see Chapter
3 ”Enrichment Analysis of Disease-related nsSNPs”). On the other hand, nsSNPsC were
found to be proportionally in high number at disordered regions, where both nsSNPsGD
and nsSNPsSC were found under-represented. This observation may suggest that residues
at disordered regions are under a lower number of structural constraints to preserve protein
function and therefore can be more easily mutated and not result in diseased states.
In addition, the structural properties of nsSNPs were also analysed by looking at the
preferences of nsSNPs in physicochemical properties and secondary structure elements.
Our results showed that nsSNPsGD exhibit distinctive structural features compared with
the control nsSNPsC . More than two-fold enrichment of nsSNPsGD at interface regions was
reported when compared with the propensity of nsSNPsC at the same region. Moreover,
nsSNPsGD are prone to cause drastic changes in amino acid type which are more likely to
affect protein stability and interactions with other proteins (in Chapter 3 ”Distinguishable
Structural Features of Disease-related nsSNPs”).
nsSNPsSC were found to share similarities with nsSNPsC in terms of structure preferences
and trends in physicochemical changes. However, the observation of nsSNPsSC are most
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likely dominated by passenger mutations which do not contribute to oncogenesis and are
the large majority in the nsSNPsSC dataset. It remains a challenge in cancer research to
pin point driver mutations by sequencing a cancer genome.
The functional properties of nsSNPs were also investigated by looking at the propensities
of nsSNPs which are spatially close to functional residues, including active sites, bind-
ing sites, PTM sites and other functional residue annotations from UniProt (Chapter 3
”Functional Specificity of nsSNPs”). nsSNPs were in general found not favoured to be
close to the functionally important residues over all three SNP data groups: propensities
(nsSNPsC , nsSNPsGD and nsSNPsSC) are lower than 1. By comparing between non-
disease and disease-related nsSNPs, we observe that both nsSNPsGD and nsSNPsSC have
a higher propensity to be close to functional residues. This may suggest that the occur-
rences of variants close to functional residues are more likely to be lethal and therefore
not observed in the population. If close-to-functional-residue mutations are transmitted
through generations, they are more likely to have a critical impact on the protein function
and subsequently lead to disease.
Another important contribution of the 3D PPIN studies is in highlighting PPI druggable
targets [128, 225, 226]. In our study, a high number of nsSNPsGD pairs occurring at
the same interfaces were found to have the tendency to cause the same type of disease
(Chapter 3 ”Co-localised Disease-related nsSNPs”). The molecular information of the
binding interface could help in designing compounds that are more specifically targeting
a protein interface containing mutations relative to a specific disease, and have more
effective therapies. Additionally, our results showed that interacting protein pairs which
have the same biological function (GO annotation) have the tendency to cause to same
types of germ-line disease. Our results support the idea that PPIs can potentially be ideal
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drug targets for specific diseases caused by specific PPIs, even though it has been very
challenging to find effective targets so far (the detailed discussion can be found in Cochran
(2000) [225] and Higueruelo et al. (2013) [128]).
3D PPINs have shown to be genuinely an effective tool for implementing large-scale studies
on biologically relevant data. Our results showed distinctive structural features of germ-
line disease SNPs from other genetic variants. A comprehensive study on the functional
and structural properties of variants can provide more sophisticated attributes for the
development of prediction methods. This encourages further application and development
on the project. We currently also look at the co-evolution analysis of co-localised interface
nsSNPs. Those co-localised nsSNPs that cause the same type of disease may be highly
associated throughout evolution (co-evolve). nsSNPsGD and nsSNPsSC are expected to
show different evolutionary relationships between co-localised nsSNP pairs since these two
types of disease-related nsSNPs affect biological system through different mechanisms and
exhibit different characteristics. These relationships will be explained in details in future
studies.
In future work, we will tackle several issues to further improve this work. First, the human
PPI dataset was obtained and integrated from a number of public databases. The database
STRING provides both experimental and predicted PPIs. These PPIs were used to extend
3D space of the human 3D PPINs. However, many of these predicted PPIs may not occur
in vivo and should be either removed from the network or filtered using stringent criteria,
such as that both proteins of interaction pairs involve in the same functional pathway or
have resolved crystal structures in the same complex.
The second area we would seek to include is to use a more appropriate statistical method
to estimate the level of differences between samples which have large sample sizes. In
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this work, the Wilcoxon Mann-Whitney test was used to estimate the level of differences
between re-sampled propensities at studied protein regions. The randomly re-sampled
propensities were generated using bootstrapping method with 10,000 replicates. However,
statistical tests can skew the results when the sample size is large [227]. The differences
between most of the compared SNP classes showed statistically significant in our results.
A method proposed by Wolfe and Hanley [227] takes into account the level of overlapping
confidence intervals between two samples. This may reduce the effect of the sample size.
Lastly, the somatic cancer variant dataset (nsSNPsSC) obtained from the COSMIC database
contains both driver and passenger variants. An effective method is required to distin-
guish drivers from passengers. One approach is to look at only the variants that occur at
driver genes. A previous work by Futreal et al. [228] listing 291 experimentally identified
driver genes provides a reliable resource for studying the mutations of the driver genes.
Although mutations found in driver genes are not necessarily driver mutations, by only
looking at these mutations we may reduce the statistical bias coming from passenger mu-
tations. Another approach is to use the prediction tools, such as MutationAssessor and
MuSiC (mentioned in Chapter 2), to predict mutations which are prone to have functional
or structural effect on proteins. A meta-analysis of the predicted results from several dif-
ferent prediction tools would generate a list of candidate mutations which are most likely
to be driver mutations. This may bring us insights into the nature of the mutations which




Stiff mean(Sizestiff ) ± SEM Flexible mean(Sizeflexible) ± SEM
nsSNPsCsurface 24,051 73.84±0.74 17,694 53.34±0.54
nsSNPsCinterface 8,152 25.70±0.29 6,600 21.11±0.25
nsSNPsCcore 34,797 110.90±2.36 7,170 24.22±0.61
nsSNPsGDsurface 1,450 91.63±2.09 979 67.37±1.63
nsSNPsGDinterface 660 32.63±0.88 469 26.91±0.76
nsSNPsGDcore 1,569 157.14±8.35 389 29.58±2.50
nsSNPsSCsurface 12,158 74.52±0.76 8,788 53.71±0.55
nsSNPsSCinterface 4,449 25.95±0.30 3,801 21.30±0.25
nsSNPsSCcore 17,102 115.93±3.91 3,795 24.75±0.66
Table A.1: Numbers of nsSNPs mapped on secondary structure elements.
nsSNPsC : general common nsSNPs; nsSNPsGD: germ-line disease nsSNPs; nsSNPsSC :
somatic cancer nsSNPs. The number of nsSNPs from each class and the average size
(length in amino acid residues) of the stiff/flexible regions are listed. The standard error
of the mean (SEM) is also reported.
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Surface Interface Core
stiff flexible stiff flexible stiff flexible
Drastic Change
nsSNPsC 5,110 5,075 1,787 1,863 2,028 1,891
nsSNPsGD 485 334 214 175 227 110
nsSNPsSC 2,994 2,716 1,258 1,333 1,394 1,040
Moderate Change
nsSNPsC 8,642 6,689 3,107 2,482 4,078 2,622
nsSNPsGD 422 296 186 147 230 137
nsSNPsSC 4,937 3,750 1,862 1,801 2,421 1,549
Table A.2: Numbers of nsSNPs mapped on secondary structure elements and
amino acid change type.
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Protein Num. Domain Surface Interface Core Disordered
Total 2,100 3,707 1,630 1,880 288
A. at functional sites
nsSNPsC 229 259 141 54 64 11
nsSNPsGD 49 61 36 15 10 6
nsSNPsSC 163 167 82 43 42 15
B. sequence-based screening
nsSNPsC 695 1,131 540 247 344 54
nsSNPsGD 112 200 108 50 42 14
nsSNPsSC 456 605 304 138 163 40
C. screening in 3D space
nsSNPsC 915 969 374 572
nsSNPsGD 140 175 62 83
nsSNPsSC 700 525 238 294
Table A.3: Numbers of nsSNPs close to functional sites.
Protein Num. Domain Surface Interface Core Disordered
Total 4,369 4,333 2,086 4,153 18,088
A. at PTM sites
nsSNPsC 814 391 162 72 157 715
nsSNPsGD 60 55 26 15 14 21
nsSNPsSC 440 258 94 68 96 320
B. sequence-based screening
nsSNPsC 1,951 1,832 730 309 793 3,288
nsSNPsGD 123 202 95 53 54 72
nsSNPsSC 1,202 1,063 403 242 418 1,431
C. screening in 3D space
nsSNPsC 1,157 1,392 543 654
nsSNPsGD 137 169 69 86
nsSNPsSC 858 864 426 405
Table A.4: Numbers of nsSNPs close to post-translational modification sites.
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Surface Interface Core Disordered
Bone 25 4 23 6
Cancer 142 48 74 73
Cardiovascular 57 5 56 41
Connective tissue 30 7 41 10
Dermatological 45 8 106 43
Developmental 63 14 42 32
Ear Nose Throat 27 4 8 12
Endocrine 120 8 101 44
Gastrointestinal 22 2 13 10
Hematological 529 10 146 60
Immunological 84 5 73 27
Metabolic 330 15 275 42
multiple 134 17 119 57
Muscular 119 6 91 39
Neurological 148 18 137 43
Nutritional 9 2 4 5
Ophthamological 81 9 72 28
Psychiatric 10 1 8 4
Renal 32 1 33 19
Respiratory 4 1 5 0
Skeletal 82 5 58 32
Table A.5: Numbers of nsSNPsGD by disease types.
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Surface Interface Core Disordered
Adrenal gland 8 4 6 7
Autonomic ganglia 87 27 78 82
Biliary tract 44 36 42 55
Bone 31 8 15 24
Breast 1,156 487 1,238 1,516
Central nervous system 663 290 641 784
Cervix 221 68 191 309
Endometrium 2,639 1,076 2,649 2,912
Eye 8 11 1 1
Haematopoietic and lymphoid tissue 981 539 990 1,138
Kidney 1,459 471 1,424 1,606
Large intestine 7,194 2,746 7,399 7,840
Liver 134 66 109 140
Lung 3,181 1,448 2,671 3,646
Meninges 45 15 47 44
Oesophagus 150 54 134 186
Ovary 1,414 548 1,468 1,650
Pancreas 446 195 463 459
Prostate 827 328 884 925
Skin 1,056 419 944 1,244
Small intestine 3 10 1 4
Soft tissue 25 36 16 46
Stomach 137 86 124 173
Testis 2 13 1 1
Thyroid 40 42 68 65
Upper aerodigestive tract 191 107 206 229
Urinary tract 491 222 493 678
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Protein–protein interaction networks (PPINs) are a powerful tool to study biological processes
in living cells. In this review, we present the progress of PPIN studies from abstract to more
detailed representations. We will focus on 3D interactome networks, which offer detailed
information at the atomic level. This information can be exploited in understanding not only
the underlying cellular mechanisms, but also how human variants and disease-causing
mutations affect protein functions and complexes’ stability. Recent studies have used
structural information on PPINs to also understand the molecular mechanisms of binding
partner selection. We will address the challenges in generating 3D PPINs due to the restricted
number of solved protein structures. Finally, some of the current use of 3D PPINs will be
discussed, highlighting their contribution to the studies in genotype–phenotype relationships
and in the optimization of targeted studies to design novel chemical compounds for
medical treatments.
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Most biological processes in a living cell, such
as transcription regulation, signal transduction
and cell motility, are mediated by protein–pro-
tein interactions (PPIs). Network representa-
tions effectively address the complexity of PPIs
in biological systems. Indeed, networks provide
a highly compact and comprehensive view of
binary relationships, in which nodes represent
proteins/genes and edges indicate functional
association or physical interactions between
protein/gene pairs (FIGURE 1A). Many studies
used network analysis to report proteins/genes
involved in a particular disease or function [1,2]
and to complement large-scale siRNA screen-
ings [3,4]. The network topological properties
of genes, including the degree of interactions,
the clustering coefficient and the betweenness,
which are the measurements of connectivity,
interconnectivity and centrality, respectively,
are often used to characterize topological fea-
tures of a network [5,6] and provide useful
insights: for example, cancer proteins were
found to have distinguishable topological fea-
tures to the other proteins. These are generally
found to be hub proteins with relatively high
centrality [7,8]. Network representations can
also be used to study the associations between
objects. In the study of Goh et al. [9], a human
diseasome bipartite network was constructed
to model associations between genes and dis-
eases. A link between a disease and a disease
gene indicates that mutations in that gene are
resulting in the specific disease. Many diseases
were found to share a common genetic origin.
This was an interesting finding which sug-
gested that diseases may not be as independent
of each other as we know from the traditional
clinical assessment.
Apart from disease-related studies, PPINs
are also often used in functional studies to
assign putative functions to newly discovered
genes [10,11] using algorithms based on the
‘Guilt-by-Association’ principle (FIGURE 1B). This
has been particularly explored for plant-specific
proteins [12–14] as the majority of these protein
functions remain unknown, and yet it is crit-
ical to understand their biological relevance
and the involving biological processes,
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including growth control and genotype–phenotype relationships
for the variety of plants.
Another approach is based on integrating genomic informa-
tion and/or PPIN with the knowledge of functional path-
ways [15], which can be retrieved from databases, such as Kyoto
Encyclopedia of Genes and Genomes (KEGG) [16]. These map-
ping has been particularly exploited for cancer studies.
Genomic perturbations attributed to diseases can be mapped
on biochemical pathways so as to obtain a pathway-level under-
standing at distinct disease states. It has been demonstrated
that when cancer patients harbor genomic alterations or
aberrant expression of different genes,
these participate in a common pathway
or have a similar effect in altering the
pathway [17,18].
These studies supported by PPINs
have brought novel insight into cellular
functional modules and the association
between genes and diseases. By integrat-
ing PPINs with the atomic-level
information (FIGURE 1C), one can under-
stand more precise details on the mech-
anisms regulating how proteins specify
their functions and how disease-causing
mutations disrupt the biologically
functional systems.
Pioneering studies in structure-based
PPINs were done by Aloy and Rus-
sell [19] who looked into atomic details
of protein interaction pairs and pro-
posed that homologous protein pairs
may interact in the same way, using the
same binding interfaces. In the effort of
bridging the gap between large-scale PPI
determination and structural data,
hybrid approaches to structure determi-
nation of macromolecular complexes
have been proposed [20–22]. Integration
of structural data at different resolution
and reliability has been successfully used
to reconstruct hybrid assembly struc-
tures that can be informative for further
PPI validation studies or in designing
new tailored structural investigations.
These 3D network studies were initially
done on the model organism yeast.
Recently, in reason of the increasing
number of available structures and inter-
action data, 3D PPINs of other organ-
isms have also become available [23,24],
including human, mouse, drosophila
and bacteria.
Recent studies [25–29] integrated pro-
tein structural information with PPINs
to give the ability to implement large-
scale studies on the association between cellular mechanism and
protein complexes. One of the major interests in exploiting
these studies is to investigate how disease-related mutations
may disrupt protein functions and ultimately affect the func-
tion of biological systems. Mutations can be classified as loss of
function, gain of function or neutral according to their effect
on protein function. These effects can be mediated by altera-
tions of the protein stability induced by the mutation [30,31].
For example, the B-RAF kinase is widely mutated in cancer
and the V600E mutant, recently observed also in patients with






















Figure 1. The scale of the biological system versus the amount of information a
protein–protein interaction network contains. (A) The human protein–protein inter-
action network. (B) ‘Guilt-by-Association’ principle in predicting protein functions. (C) 3D
RAF1 subnetwork containing information from system level to atomic level. The nodes
represent proteins, whereas the edges are annotated with protein complexes. (D) The
structure of protein complex. The interface regions are shown with shape sphere and
mapped with disease-causing nsSNVs (colored in red). (E) The atomic-level view of inter-
face with nsSNVs. (F) A drug inhibits the binding pocket.
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conformation of the kinase. This gain-of-function mutant keeps
B-RAF in the active state and consequently increases the activa-
tion of another kinase ERK [32]. Mutations can affect protein
function also by modifying the affinity of the protein for its
partners. For example, mutations derived from Glioblastoma
patients have been recently shown to destabilize the complexes
of the proteins involved in the disease pathogenesis, mainly
through a decrease of the electrostatic contributions to the
binding energy [27]. Drastic amino acid changes at the protein
interface, where a protein is in physical contact with another
protein, can significantly change the binding energy of the
interaction. In particular, the occurrence of mutations at the
interface hot spot residues, which contribute the most to the
binding energy [33,34], are most likely to have impact on the
interaction, so that the proteins would either loose interactions
with the partner proteins or gain interactions with new binding
proteins. Additionally, protein function can be altered by muta-
tions occurring at allosteric sites. Indeed, allosteric mutations
can disrupt or promote the binding of allosteric modulators,
affect the communication pathways between the allosteric and
orthosteric sites and modify the relative proportion of inactive/
active conformations [35,36]. For example, different cancer-
related mutations in kinases have been shown to involve a shift-
ing in the relative population of the inactive/active states [37,38].
Besides providing insight into the impact on the complex
functionality of disease-causing mutations, 3D PPINs can be
used for large-scale screenings of drug targets to compensate
experimental drug compound screening methods [39]. A num-
ber of approaches have been developed in the recent years to
exploit PPINs in drug discovery, as the cellular network and
the surrounding environment are essential part of the process
of efficient drug targeting and delivering. By implementing
large-scale screening over protein molecular properties, one
could identify new target proteins and potential binding sites
of drug compounds. In particular, PPINs can be used to iden-
tify PPI inhibitors. Targeting PPI is still one of the most chal-
lenging task in drug design, owing to the significant differences
between interfaces in PPIs and small molecule-binding sites.
However, specific properties embedded in PPI interfaces and
needed for partners recognition can be exploited to identify
drug compound targets [40–44]. Indeed, there are increasing
examples of targeting PPIs (FIGURE 1F) with drugs that can bind
to transient and dynamic pockets in orthosteric or allosteric
sites (for a review on the subject, see Engin et al. [45] and refer-
ences therein). In targeting PPIs, people are also exploiting pro-
tein interface motifs to identify potential off-target drugs [46].
Databases such as Interactome3D [23] and INstruct [24] provide
PPINs annotated with protein complexes and are essential to
large-scale screening approaches targeting protein interfaces in
drug design [47].
Another interesting use of targeting PPIN, pathways and drug
action mechanisms is the identification of proteins that induce
drug side effects [48]. Drug side effects are often the most undesir-
able outcomes from medical treatment, frequently caused by the
binding between drug compounds and off-target proteins.
Adverse drug reaction was reported to be one of the major causes
of mortality and morbidity over the last decades [49]. Polyphar-
macology approaches have become popular in complementing
the classical ‘one-drug one-target’ paradigm [50].
Still, the bottleneck of systematic screening of binding pock-
ets for drug compounds in silico lays on the limited availability
of experimental structures. Homology modeling can be used in
generating 3D protein models to compensate this limita-
tion [51,52]. However, high-quality structures are essential for
binding pocket detection. Model refinement procedures can
help in obtaining a more realistic structure for these drug
target-binding studies [53]. However, additional challenges in
protein complex prediction are in that often proteins are sub-
ject to conformational changes to attain specific binding modes.
A special case is when these functional states are induced by
allosteric sites signaling, generally not easy to observe experi-
mentally [54]. Thus, conformational change perturbations are
usually not taken into account in protein complexes
modeling procedures.
In the following sections, we discuss the availability and
quality of PPI data sets, as well as the current state of high-
throughput experimental methods for PPIs detection since they
are fundamental to build a 3D PPIN. We particularly focus on
recent applications of 3D PPIN, highlighting strengths and dis-
cussing limitations related to the availability of structural data
for human proteins. Finally, we briefly comment on how 3D
PPIN could contribute to the design of novel-targeted thera-
pies, particularly useful to the advancement of personalized
medicine.
Protein–protein interaction data
High-throughput experimental methods have given the possibil-
ity to build PPINs of entire organisms, which in some cases
(e.g., yeast) [55] are deemed close to complete. They include
detection of direct interactions by yeast two-hybrid assays and
detection of protein complexes by affinity purification-mass
spectrometry (AP-MS). Literature curation and annotation are
another useful source for PPI data sets, often extracting infor-
mation obtained from small-scale experiments, such as Fluores-
cence Resonance Energy Transfer or other biophysical
investigations. However, these collected data sets are usually
biased toward the proteins that have been most extensively
studied and are not large scale, due to constraints in the detec-
tion methods. In 2008, it was estimated that about
650,000 PPIs should occur in humans [56] and so far about
one-tenth of the estimated human interactions have been
observed experimentally [57]. Publicly available databases, such
as HPRD [58], BioGRID [59], DIP [60], IntAct [61], MINT [62]
and STRING [63], provide platforms to access PPIs curated
data sets.
Although the high-throughput experiment techniques are
progressing to obtain complete pictures of biological systems,
low reproducibility of the data has raised concern about the
data quality. Braun [64] pointed out that the overlap of yeast
PPI data sets derived from AP-MS experiments between two
3D structure knowledge & PPIN Review
www.expert-reviews.com 513
labs could be as low as 20%. This may be ascribed to different
reasons including the absence of the same standardized experi-
ment protocols and biased sampling. Varjosalo and col-
leagues [65] demonstrated that high-throughput PPI experiments
are highly reproducible when performed by two different labs
if the protocols with the same standardized workflows are used.
Moreover, to diminish bias sampling, they used 32 human kin-
ases as bait proteins with a different domain composition,
expressed in different tissues and involved in different biological
processes. Analogously, Havugimana and colleagues [66] gener-
ated a pipeline with stringent experiment procedures and apply-
ing computational methods to detect high-abundance
components and identify functionally unrelated protein pairs.
Proteomic profiles were used to assess the abundance, reducing
the number of false-positive interactions from protein pairs that
in vivo are not expressed at the same time and cellular space.
Scientists in the AP-MS field are developing experimental
approaches to mitigate some of these inefficiencies, using, for
example, replicated and control experiments and relative quan-
tification to enhance sensitivity and/or by developing confi-
dence scores to select specific PPIs [67–69]. Apart from
experiment protocols, many studies also suggested the need of
data standardization [70,71] and validation [67,72]. The Interna-
tional Molecular Exchange consortium provides the controlled
vocabularies and standardized data formats that have been
adopted by major databases [73,74]. Statistical methods [75] and
structural information are also suggested for the validation of
PPIs before they are deposited to the databases.
Additionally, a number of computational methods have
been developed to compensate the experimental methods and
expand the space of PPINs based on strategies such as co-
evolution [76] and homology modeling [77] (for a recent review
on computational prediction methods, see Mosca et al. [71]).
However, high-confidence PPI data with experimental evi-
dence are fundamental to build 3D PPINs, which could carry
out more robust studies in disease-related mutations and drug
target identification.
The construction of 3D PPINs
As previously mentioned, PPIN is a useful tool in identifying
disease or functional relationships between proteins. Yet,
system-level representations of biological processes provide very
limited information on answering crucial questions, such as
how a protein recognizes its partner proteins, or which region
of its surface binds to its partner proteins. It requires atomic-
level information to understand binding mechanisms. However,
mapping structural information onto networks remains a chal-
lenge due to the gap between the number of known proteins
and the number of solved protein structures and some types of
proteins are under-represented in structure databases such as
membrane proteins. So far, the Protein Data Bank [78] stores
roughly around 5,000 human protein structures with many of
them containing only partial structures.
To tackle this problem, earlier work in developing 3D
molecular interaction networks, including iPfam [79] and
3did [80], analyzed the structures of protein complexes at
domain level. The domain-based interactions are supported by
both inter- and intraspecies co-crystal structures, and they
include interactions between domains belonging both to the
same and to different proteins. 3did covers more than
4,000 distinct domains that are about one-third of the total
number of Pfam domains [81]. Importantly, domains are the
basic evolutionary and functional units of proteins. Proteins
with domains in a common superfamily are considered more
likely to be evolutionarily related [82]. By looking at the molec-
ular details of protein domain interactions, one could identify
the domains that are functionally important in mediating PPIs.
To increase the coverage of structures in PPINs, the two recent
databases INstruct [24] and Interactome3D [23] implement two
different approaches both based on the use of homologous struc-
tures. One should be aware that PPI predictions using homolo-
gous structures can be of different nature. One is to use
homologous protein structures of a protein pairs to predict the
possibility of interaction, which is not detected from experimen-
tal methods. The other is to predict structure complex of a pro-
tein pair, which is known to interact from experimental methods
and therefore trying to enrich with structural information the
available large-scale screens. The following discussions are based
on the second strategy to predict the protein complexes. The
pipeline of INstruct to generate a 3D PPIN starts from binary
interaction data sets from different publicly available databases.
Each interacting pair is then annotated with the corresponding
co-crystal structure if available or with co-crystal structures of
homologous proteins. It should be noted that the resulting struc-
tural annotation of protein pairs with homologous co-crystals is
only approximate. The database provides 3D PPIN data of
human and six other most studied model organisms, where
human 3D PPIN contains 6,585 interactions between 3,627 pro-
teins. A different strategy was used for Interactome3D, where the
structural coverage of human PPIN was increased by modeling
interacting pairs with missing structural data using Modeller [83].
This provides a more precise representation of interface regions
of interacting protein pairs. Interface residues are identified by
calculating the distance of residues from protein pairs. The data-
base provides human 3D PPIN, which contains 6,473 interac-
tions between 4,239 proteins.
One may also use predicted protein structures obtained from
reliable resources to compensate the limitation of solved protein
structures. A recent project Genome3D [84] integrates UK-based
structural resources, including Gene3D [85], FUGUE [86] and
four other structural prediction resources [14,87–89]. The aims of
this project are to provide biologists with a platform to com-
pare the predictions from those resources that were developed
with different algorithms, and to choose the prediction out-
comes that are more reliable. Those predicted structures could
help to expand the size of 3D PPINs.
To identify or even predict the proteins that can be acting
together, one could use available structural information.
A study by Kar et al. [90], for instance, looked at the structural
features of cancer proteins. Cancer proteins are well known to
Review Lu, Fornili & Fraternali
514 Expert Rev. Proteomics 10(6), (2013)
be involved in biological processes related to, for example,
DNA repair and cell growth. In this study, 10 functional path-
ways were selected according to the Cancer Cell Map [201].
Each protein pair in a given functional pathway is annotated
with structural information obtained by running PRISM [91], a
software to explore the known protein–protein interface-
binding modes and predict analogous cases. PRISM can predict
the protein interaction by searching interface with similar back-
bone geometry in the interface library. In this way, co-crystal
structures are not strictly required to build the PPIN of the
pathway. This method is beneficial for smaller scale studies
with interests in proteins in particular functional pathways and
save computational time to construct a 3D PPIN of an
entire proteome.
To summarize, in this section, we have reviewed some of the
recent approaches to generate 3D PPINs. As it will be shown
in the following sections, building increasingly complete 3D
PPINs is essential to interpret biological systems, provide
insight into complex cellular mechanisms and rationalize geno-
type–phenotype relationships.
Protein interaction interfaces
The ability of proteins to recognize and bind their partners is
essential to biological processes. Protein interfaces, where pro-
teins have physical contact with their partner proteins, are
believed to embed crucial properties that mediate PPIs. Both
experiments and computational analyses have shown that pro-
tein interfaces mediate PPIs through specific molecular proper-
ties, including sequence motifs [46,92], backbone geometry [93],
residue types [94], interface hot spots [33,95] and correlated
changes in the two interfaces.
Each interface of a protein is composed of several discon-
tinuous patches. Two estimates have been commonly used to
define the interface regions. The first approach is to calculate
the distances between residue pairs from two proteins in a
co-crystal structure [23,43]. Two residues are considered as
interacting if their distance is within a predefined threshold.
This value may depend on the group of residue atoms that is
used to calculate the inter-residue distance. Typical threshold
values are 4–5 A˚ on the distance between any pair of atoms
from the two residues [80,96] or 9 A˚ on the distance between
Ca or Cb atoms [43]. The sum of atomic van der Waals radii
+ 0.5 A˚ is another frequently used distance threshold [97].
More sophisticated criteria use different thresholds for differ-
ent types of interactions (e.g., hydrogen bonds, salt bridges
and van der Waals interactions) [23]. The second approach
compares the solvent accessible surface area (SASA) of the
protein complex with that of the single components to evalu-
ate the area buried upon complex formation (interface area).
For example, residues can be considered as part of the inter-
face if their total or side chain buried solvent accessible sur-
face area is larger than 0–1 A˚2 [98,99]. The calculation of the
buried area can be implemented in automated approaches
such as POPSCOMP [100]. Precompiled values for protein
complexes are also available from databases such as 3did and
PIBASE [101]. For protein pairs where the structure of the
single proteins is available but not that of the complex,
molecular docking methods, such as FiberDock [102], can be
used to predict the interface regions.
In one of the leading studies on biologic structural networks,
Kim and colleagues [103], classified hub proteins into two
groups according to the number of their interfaces: multi-
interface hubs and singlish-interface hubs. The two groups
were shown to have different evolutionary properties. In partic-
ular, only multi-interface hubs turned out to be significantly
more essential and slow evolving compared with the average.
Since early studies considered all hub proteins to be essen-
tial [104,105], this shows that the integration of sequential and
structural information on protein interfaces can increase the
precision in identifying functionally important proteins within
biological systems.
The importance of interfaces for protein functions and bio-
logical processes was further confirmed in recent studies by
looking at the occurrences of disease-associated mutations [26,106],
where the interface regions were found to be enriched in
disease-causing mutations. This implies that a residue change at
these region is more likely to disrupt protein functions and
lead to diseases. In a follow-up study by the same group [107],
further annotations were given to the mutations mapped on
3D PPIN. Dominant truncating disease mutations were found
to have different pattern to other classes of mutations with no
preference occurring at interface regions. Moreover, recessive
mutations co-localized on the same interface showed the ten-
dency to cause the same disease.
Increasing the level of detail in the description of protein
interfaces further highlights the importance of structural prop-
erties in determining the protein function. For example, pro-
miscuous binding sites, which are essential for hub proteins to
interact with many different partners, can be identified by
mapping interactions with multiple partners on the protein sur-
face. Promiscuous sites have been shown to possess specific
properties in terms of amino acid composition [108,109], solvent
accessibility [110], packing [97] and conformational flexibil-
ity [111,112], mainly related with their increased capacity to adapt
to different partners. The biological relevance of promiscuous
residues is further confirmed by a recent study from our labora-
tory [111], showing that they are less enriched in non-synony-
mous single-nucleotide variations (nsSNVs). This finding
suggests that residues in promiscuous positions have a reduced
tolerance to genetic variations, related to the necessity to pre-
serve their binding polyvalence.
Although key challenges remain in performing interactome-
scale studies on protein interface regions due to the low avail-
ability of protein structures, computational approaches may
help in overcoming this limitation. Gao and Skolnick [93]
found that many protein complexes have similar interfaces even
if the overall structure of the single components is different.
Thus, they argued that even though there are only a small frac-
tion of proteins with solved structures, the protein interface
library is close to complete. This is the fundamental idea
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behind protein-binding pocket searches [113,114] and PPI predic-
tions that use interface structure similarity scoring [77,91] in
order to increase the structural coverage of 3D PPIN.
How 3D PPINs contribute to biology and biomedical
sciences
Advances in genome-sequencing techniques and large-scale
genome-sequencing projects, including the 1000 Genomes
Project [115] and the International HapMap Project [116], are
boosting the amount of available gene variation data. Data-
bases, including dbSNP [117], OMIM [118], COSMIC [119],
HGMD [120] and Exome Variant Server [202], provide online
interfaces to easily access gene variation data sets and serve
with different purposes. The challenge is now to develop
methods and tools to extract useful information from this
increasing amount of data. In particular, it will be essential to
understand what information those mutations are carrying,
how we can use those gene variation data to unravel the
underlying cellular mechanisms and how disease-causing
mutations lead to diseases [121,27]. To answer these questions,
atomic-level information of protein complexes is crucial to
provide the biological features of disease-related proteins and
disease-causing mutations. Moreover, by implementing large-
scale studies with 3D PPINs, which contain information from
system level to atomic level, one may find explanations for
the effects of these mutations. For example, Kar et al. [90]
implemented human structural protein interface network, in
which the edges represent binding interfaces between protein
pairs obtained from either known or predicted structures from
PRISM. Their results show that cancer proteins tend to be
hubs in the network. The mutations occurring at cancer pro-
tein interfaces, disrupting protein bindings and causing loss of
protein functions, have greater impact on biological systems.
The binding interfaces of cancer proteins were also shown to
have specific properties; they are significantly smaller, more
planar, less compact and less hydrophobic than interfaces in
noncancer proteins. These specific features of cancer protein
interfaces may be used for the identification of new targets
and drug candidates in cancer therapies. The results demon-
strated how 3D PPINs can enable more comprehensive stud-
ies in biological systems with informative outcomes. Besides,
3D PPINs can be effectively used in high-throughput screen-
ing for drug targets. Indeed, PPIs are promising druggable
targets since their selective inhibition [122] can be used to regu-
late particular functions in biological systems. 3D PPINs, by
representing in a synthetic and comprehensive way the associ-
ations between a target protein and its partner proteins, are
an invaluable tool to understand the possible effects of inhib-
iting the binding interfaces of the target protein. All these
examples show how 3D PPINs can give an essential contribu-
tion to Biomedical Sciences.
Expert commentary
The studies of PPINs have progressed from system-level rep-
resentations of biological systems to more detailed
representations annotated with atomic information. The inte-
gration of data from the currently available biological data-
bases has proven to be essential to carry out comprehensive
studies on cellular mechanisms and the causes of their disrup-
tion. 3D PPINs analysis has been used to study the role of
disease-causing mutations. So far, despite the general agree-
ment on the propensity of disease-related mutations for pro-
tein interface regions, the general characteristics of these
mutations and how they affect biological functions remain
challenging. Still, 3D PPINs analysis is very important to
unravel the features of these mutations and their impact on
protein functions. In particular, the identification of proper-
ties specific to pathogenic mutants is crucial to develop meth-
ods for the prediction of disease-related mutations. Besides,
3D PPINs analysis can also help biologists to effectively
search for possible targets for disease treatment as PPIs are
ideal drug targets [122] to regulate biological functions, and
the structural information in 3D networks provides the guid-
ance for the design of drug compounds in the early stage
development. 3D PPINs provide fundamental materials for
the screening of off-target PPIs. The use of these preliminary
investigation strategies could effectively reduce time and cost
in drug development. The increased understanding of the
pathogenic mechanisms triggered by disease mutations, and
of the activity of drug compounds in the cell, combined with
personal genome sequencing profiles, will promote the devel-
opment and delivery of more effective personalized clinical
treatments in the foreseeable future.
Five-year view
The studies using 3D PPINs are a relatively new research
field. The bottleneck in the generation of complete 3D
PPINs lays in the limitation of available experimental data
on genome sequences and protein structures. With the rapid
progressing of experimental technologies and bioinformatics
approaches, more biological data will become available to
provide a more complete view of biological systems. In the
coming years, the importance of protein-binding mecha-
nisms and the general characteristics of disease mutations
will be better understood. Therefore, it will be possible to
develop more sensitive predictors of disease-causing muta-
tions, resulting in further progress toward effective personal-
ized medical treatments.
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Key issues
• Currently, the number of solved protein structures is relatively small when compared with the number of known proteins for each
species. Although homologous structure modeling could narrow the gap, a close-to-complete map of biological system requires a higher
number of available structures.
• Modeling protein complexes remains challenging.
• Some types of proteins are significantly under-represented in protein structure databases such as membrane proteins. These proteins are
also determinant for cellular signaling and drug target studies.
• It is now timely to develop methods and tools to extract useful information from the large amount of data generated by large-scale
genome, metabolome, transcriptome and proteome projects.
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